<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">102434</article-id><article-id pub-id-type="doi">10.7554/eLife.102434</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.102434.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology</subject></subj-group></article-categories><title-group><article-title>Oncogenic and teratogenic effects of <italic>Trp53</italic><sup>Y217C</sup>, an inflammation-prone mouse model of the human hotspot mutant <italic>TP53</italic><sup>Y220C</sup></article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Jaber</surname><given-names>Sara</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Eldawra</surname><given-names>Eliana</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Rakotopare</surname><given-names>Jeanne</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Simeonova</surname><given-names>Iva</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Lejour</surname><given-names>Vincent</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2797-1507</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Gabriel</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Cañeque</surname><given-names>Tatiana</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Volochtchouk</surname><given-names>Vitalina</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Licaj</surname><given-names>Monika</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Fajac</surname><given-names>Anne</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Rodriguez</surname><given-names>Raphaël</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Morillon</surname><given-names>Antonin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0575-5264</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Bardot</surname><given-names>Boris</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4976-9593</contrib-id><email>boris.bardot@curie.fr</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Toledo</surname><given-names>Franck</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3798-4106</contrib-id><email>franck.toledo@sorbonne-universite.fr</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02en5vm52</institution-id><institution>Genetics of Tumor Suppression, Institut Curie, CNRS UMR3244, Sorbonne University, PSL University</institution></institution-wrap><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02en5vm52</institution-id><institution>Chromatin Dynamics, Institut Curie, CNRS UMR3664, Sorbonne University, PSL University</institution></institution-wrap><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04t0gwh46</institution-id><institution>Non Coding RNA, Epigenetic and Genome Fluidity, Institut Curie, CNRS UMR3244, Sorbonne University, PSL University</institution></institution-wrap><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04t0gwh46</institution-id><institution>Chemical Biology, Institut Curie, CNRS UMR3666, INSERM U1143, PSL University</institution></institution-wrap><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03xjwb503</institution-id><institution>Signaling and Neural Crest Development, Institut Curie, CNRS UMR3347, INSERM U1021, Université Paris-Saclay, PSL University</institution></institution-wrap><addr-line><named-content content-type="city">Orsay</named-content></addr-line><country>France</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02en5vm52</institution-id><institution>Hematopoietic and Leukemic Development, Centre de Recherche Saint-Antoine, INSERM UMRS938, Sorbonne University</institution></institution-wrap><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Lal</surname><given-names>Ashish</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/040gcmg81</institution-id><institution>National Cancer Institute</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>El-Deiry</surname><given-names>Wafik S</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05gq02987</institution-id><institution>Brown University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>14</day><month>04</month><year>2025</year></pub-date><volume>13</volume><elocation-id>RP102434</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-09-26"><day>26</day><month>09</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-09-29"><day>29</day><month>09</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.09.26.615223"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-12-24"><day>24</day><month>12</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.102434.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-03-26"><day>26</day><month>03</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.102434.2"/></event></pub-history><permissions><copyright-statement>© 2024, Jaber, Eldawra, Rakotopare et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Jaber, Eldawra, Rakotopare et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-102434-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-102434-figures-v2.pdf"/><abstract><p>Missense ‘hotspot’ mutations localized in six p53 codons account for 20% of <italic>TP53</italic> mutations in human cancers. Hotspot p53 mutants have lost the tumor suppressive functions of the wildtype protein, but whether and how they may gain additional functions promoting tumorigenesis remain controversial. Here, we generated <italic>Trp53</italic><sup>Y217C</sup>, a mouse model of the human hotspot mutant <italic>TP53</italic><sup>Y220C</sup>. DNA damage responses were lost in <italic>Trp53</italic><sup>Y217C/Y217C</sup> (<italic>Trp53</italic><sup>YC/YC</sup>) cells, and <italic>Trp53</italic><sup>YC/YC</sup> fibroblasts exhibited increased chromosome instability compared to <italic>Trp53</italic><sup>-/-</sup> cells. Furthermore, <italic>Trp53</italic><sup>YC/YC</sup> male mice died earlier than <italic>Trp53</italic><sup>-/-</sup> males, with more aggressive thymic lymphomas. This correlated with an increased expression of inflammation-related genes in <italic>Trp53</italic><sup>YC/YC</sup> thymic cells compared to <italic>Trp53</italic><sup>-/-</sup> cells. Surprisingly, we recovered only one <italic>Trp53</italic><sup>YC/YC</sup> female for 22 <italic>Trp53</italic><sup>YC/YC</sup> males at weaning, a skewed distribution explained by a high frequency of <italic>Trp53</italic><sup>YC/YC</sup> female embryos with exencephaly and the death of most <italic>Trp53</italic><sup>YC/YC</sup> female neonates. Strikingly, however, when we treated pregnant females with the anti-inflammatory drug supformin (LCC-12), we observed a fivefold increase in the proportion of viable <italic>Trp53</italic><sup>YC/YC</sup> weaned females in their progeny. Together, these data suggest that the p53<sup>Y217C</sup> mutation not only abrogates wildtype p53 functions but also promotes inflammation, with oncogenic effects in males and teratogenic effects in females.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>hotspot p53 mutant</kwd><kwd>p53Y220C</kwd><kwd>gain of function</kwd><kwd>exencephaly</kwd><kwd>inflammation</kwd><kwd>sex-specific effects</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004097</institution-id><institution>Fondation ARC pour la Recherche sur le Cancer</institution></institution-wrap></funding-source><award-id>Projet</award-id><principal-award-recipient><name><surname>Toledo</surname><given-names>Franck</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004099</institution-id><institution>Ligue Contre le Cancer</institution></institution-wrap></funding-source><award-id>Labellisation 14-18</award-id><principal-award-recipient><name><surname>Toledo</surname><given-names>Franck</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100014808</institution-id><institution>Groupement des Entreprises Françaises dans la lutte contre le Cancer</institution></institution-wrap></funding-source><award-id>Projet Métastases</award-id><principal-award-recipient><name><surname>Toledo</surname><given-names>Franck</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000781</institution-id><institution>European Research Council</institution></institution-wrap></funding-source><award-id award-id-type="doi">10.3030/875532</award-id><principal-award-recipient><name><surname>Morillon</surname><given-names>Antonin</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>In a mouse model of the hotspot mutant <italic>TP53</italic><sup>Y220C</sup>, the mutant p53 exhibited oncogenic gain of function in males and teratogenic gain of function in females, both correlated with inflammation.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Somatic alterations in the <italic>TP53</italic> gene, encoding the tumor suppressor p53, are the most common events in human tumors (<xref ref-type="bibr" rid="bib35">Hollstein et al., 1991</xref>). The p53 protein is a stress sensor stabilized and activated in response to potentially oncogenic insults. In its tetrameric active form, wildtype (WT) p53 can trigger a transcriptional program to induce various responses including cell cycle arrest, senescence, apoptosis, or metabolic changes (<xref ref-type="bibr" rid="bib7">Beckerman and Prives, 2010</xref>). In human cancers, about 75% of all <italic>TP53</italic> alterations are missense mutations, and the eight most frequent (‘hotspot’) missense mutations (R175H, Y220C, G245S, R248Q, R248W, R273H, R273C, and R282W) affect six residues localized in the p53 DNA-binding domain (DBD) and account for 20% of all <italic>TP53</italic> mutations (<xref ref-type="bibr" rid="bib31">Hainaut and Pfeifer, 2016</xref>). The fact that most <italic>TP53</italic> mutations are missense substitutions suggested that cells expressing mutant p53 might have a selective advantage over cells lacking p53, and evidence for this was first gained by expressing various p53 mutants in p53-null cells and observing enhanced tumorigenic potential in nude mice or increased plating efficiency in agar cell culture (<xref ref-type="bibr" rid="bib17">Dittmer et al., 1993</xref>). Mouse models expressing hotspot p53 mutants next helped to define potential mechanisms accounting for accelerated tumorigenesis. First, a dominant-negative effect (DNE) may be observed in heterozygotes, if the mutant p53 inhibits the WT p53 protein in hetero-tetramers (<xref ref-type="bibr" rid="bib27">Gencel-Augusto and Lozano, 2020</xref>). Evidence that this mechanism accounts for accelerated tumorigenesis was notably reported in human leukemia (<xref ref-type="bibr" rid="bib11">Boettcher et al., 2019</xref>). A second mechanism is a gain of function (GOF), i.e., the acquisition by mutant p53 of new oncogenic properties (<xref ref-type="bibr" rid="bib3">Amelio and Melino, 2020</xref>; <xref ref-type="bibr" rid="bib78">Stein et al., 2020</xref>). Although the DNA sequence specificity of p53 mutants is impaired, leading to a loss of WT functions (loss of function [LOF]), many p53 mutant proteins are stabilized in the cell and might engage in aberrant interactions with other transcription factors, chromatin-modifying complexes, or DNA helicase subunits, leading to the acquisition of GOF phenotypes (<xref ref-type="bibr" rid="bib47">Kim and Deppert, 2007</xref>; <xref ref-type="bibr" rid="bib65">Pfister and Prives, 2017</xref>; <xref ref-type="bibr" rid="bib97">Zhao et al., 2024</xref>). However, a few recent studies challenged the pathological importance of mutant p53 GOF, or at least its relevance in anti-cancer therapeutic strategies (<xref ref-type="bibr" rid="bib5">Aubrey et al., 2018</xref>; <xref ref-type="bibr" rid="bib11">Boettcher et al., 2019</xref>; <xref ref-type="bibr" rid="bib90">Wang et al., 2024</xref>). An alternative hypothesis emerged, postulating that the tumorigenic properties of a p53 mutant might result from a separation of function (SOF), if the mutant retains pro-proliferative or pro-survival functions of WT p53 while losing its tumor suppressive activities (<xref ref-type="bibr" rid="bib46">Kennedy and Lowe, 2022</xref>). The concept of SOF was first proposed for <italic>TP53</italic> exon 6 truncating mutations, which mimic a naturally occurring alternative p53 splice variant (<xref ref-type="bibr" rid="bib73">Shirole et al., 2016</xref>), but may apply to some p53 missense mutations, e.g., p53<sup>R248W</sup> (<xref ref-type="bibr" rid="bib38">Humpton et al., 2018</xref>). Importantly, the analysis of various mutant p53 alleles in vivo appears crucial for a better understanding of their contribution to tumorigenesis, because GOF/SOF phenotypes may vary depending on the mutated residue, its specific mutation, the cellular context, or genetic background (<xref ref-type="bibr" rid="bib16">Dibra et al., 2024</xref>; <xref ref-type="bibr" rid="bib34">Hanel et al., 2013</xref>; <xref ref-type="bibr" rid="bib43">Kadosh et al., 2020</xref>; <xref ref-type="bibr" rid="bib48">Kim and Lozano, 2018</xref>; <xref ref-type="bibr" rid="bib49">Kotler et al., 2018</xref>; <xref ref-type="bibr" rid="bib58">McCann et al., 2022</xref>; <xref ref-type="bibr" rid="bib91">Xiong et al., 2022</xref>).</p><p>In human cancers, the <italic>TP53<sup>Y220C</sup></italic> mutation is the most frequent missense mutation outside of the DNA-binding surface of p53 (<xref ref-type="bibr" rid="bib31">Hainaut and Pfeifer, 2016</xref>). The somatic <italic>TP53<sup>Y220C</sup></italic> mutation accounts for over 100,000 new cancer cases per year worldwide, including solid tumors and myeloid neoplasms, and a germline <italic>TP53<sup>Y220C</sup></italic> mutation was reported in 15 families with the Li-Fraumeni syndrome of cancer predisposition (<xref ref-type="bibr" rid="bib12">Bouaoun et al., 2016</xref>; <xref ref-type="bibr" rid="bib28">Gener-Ricos et al., 2024</xref>). The mutation causes a structural change in the DBD localized at the periphery of the β-sandwich region of the protein, far from the surface contact of DNA. The mutation from a tyrosine to a cysteine markedly lowers the thermodynamic stability of the DBD, leading to a largely unfolded and inactive protein at body temperature (<xref ref-type="bibr" rid="bib41">Joerger et al., 2006</xref>), and a molecule designed to bind p53<sup>Y220C</sup> and restore WT protein conformation appears as a promising anti-cancer drug (<xref ref-type="bibr" rid="bib19">Dumbrava et al., 2022</xref>). Analyses of the impact of p53<sup>Y220C</sup> in cancer cell lines led to conflicting results. On one hand, overexpression of p53<sup>Y220C</sup> in a p53-null cell line increased its capacity for migration or invasion (<xref ref-type="bibr" rid="bib98">Zhou et al., 2022</xref>), and a decreased expression of p53<sup>Y220C</sup>, caused by RNA interference or various chemical compounds, promoted cell death or decreased the migratory or invasive capacities of cells (<xref ref-type="bibr" rid="bib83">Tseng et al., 2022</xref>; <xref ref-type="bibr" rid="bib87">Vikhanskaya et al., 2007</xref>; <xref ref-type="bibr" rid="bib98">Zhou et al., 2022</xref>). On the other hand, the removal by CRISPR/Cas9 of p53 mutants with reported GOF - including p53<sup>Y220C</sup> - in diverse cancer cell lines had no significant impact on cell survival or proliferation, and the cell death caused by RNA interference against p53<sup>Y220C</sup> might result from nonspecific toxic effects (<xref ref-type="bibr" rid="bib90">Wang et al., 2024</xref>). Here, to gain a better understanding of the impact of the p53<sup>Y220C</sup> mutation in vivo, we generated a mouse model with a targeted <italic>Trp53</italic><sup>Y217C</sup> mutation - the mouse equivalent to human <italic>TP53</italic><sup>Y220C</sup> (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>) - and analyzed animals and cells carrying one or two copies of the mutant allele.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Targeting of a p53<sup>Y217C</sup> mutation in the mouse</title><p>We used homologous recombination in 129/SvJ embryonic stem (ES) cells to target the p53<sup>Y217C</sup> mutation at the mouse <italic>Trp53</italic> locus. Mice expressing p53<sup>Y217C</sup> conditionally were generated by using a targeting vector containing transcriptional stops flanked by LoxP sites (LSL) upstream of coding sequences, and the p53<sup>Y217C</sup> mutation in exon 6 (<xref ref-type="fig" rid="fig1">Figure 1A–D</xref>). <italic>Trp53</italic><sup>+/LSL-Y217C</sup> mice were then crossed with mice carrying the PGK-Cre transgene (<xref ref-type="bibr" rid="bib51">Lallemand et al., 1998</xref>) to excise the LSL cassette and obtain <italic>Trp53</italic><sup>+/Y217C</sup> mice, expressing the mutant protein constitutively. After two backcrosses over a C57BL/6J background, we prepared mouse embryonic fibroblasts (MEFs) from intercrosses of <italic>Trp53</italic><sup>+/Y217C</sup> mice (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). We extracted RNAs from <italic>Trp53</italic><sup>Y217C/Y217C</sup> (<italic>Trp53</italic><sup>YC/YC</sup>) MEFs then sequenced p53 mRNAs to verify that the p53<sup>Y217C</sup> coding sequence was identical to the wildtype p53 (p53<sup>WT</sup>) sequence, except for the desired missense mutation and a silent mutation introduced to facilitate mouse genotyping (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). The quantification of p53 mRNA levels from WT and <italic>Trp53</italic><sup>YC/YC</sup> MEFs next revealed similar transcription from both alleles (<xref ref-type="fig" rid="fig1">Figure 1G</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Targeting the Y217C missense mutation at the mouse <italic>Trp53</italic> locus.</title><p>(<bold>A</bold>) Targeting strategy. The wildtype (WT) <italic>Trp53</italic> gene is within a 17-kb-long EcoRI (RI) fragment (black boxes are for coding sequences and white boxes for UTRs). The targeting construct contains: (1) a 1.5-kb-long 5’ homology region; (2) a Lox-Stop-Lox (LSL) cassette with a <italic>neomycin</italic> selection gene (Neo), four transcriptional stops (STOP) and an EcoRI site, flanked by LoxP sites (arrowheads); (3) p53 coding exons, including the Y217C (YC) missense mutation in exon 6 (asterisk) and an additional BanII site; (4) a 2.8-kb-long 3’ homology region; and (5) the diphteria α-toxin (DTA) gene for targeting enrichment. Proper recombinants with a <italic>Trp53</italic><sup>LSL-Y217C</sup> allele, resulting from the described crossing-overs, were G418 resistant. They were identified by a 2.4-kb-long band after PCR with primers a and b, and confirmed by bands of 635 and 224 bp after PCR with primers c and d and BanII digestion. They were also verified by Southern blot with the indicated probe as containing a 10.5 kb EcoRI band. Two recombinant ES clones were injected into blastocysts to generate chimeras, and germline transmission was verified by genotyping with primers c and d and BanII digestion. Excision of the LSL cassette was performed in vivo, by breeding <italic>Trp53</italic><sup>+/LSL-Y217C</sup> male mice with females carrying the PGK-<italic>Cre</italic> transgene, to obtain mice with a <italic>Trp53</italic><sup>Y217C</sup> allele. (<bold>B–D</bold>) Screening of recombinant ES clones (+) by PCR with primers a and b (<bold>B</bold>); PCR with primers c and d then BanII digestion (<bold>C</bold>); Southern blot (<bold>D</bold>). (<bold>E</bold>) Genotyping of mouse embryonic fibroblasts (MEFs) from an intercross of <italic>Trp53</italic><sup>+/Y217C</sup> mice, by PCR with primers c and d and BanII digestion. (<bold>F</bold>) <italic>Trp53</italic><sup>Y217C</sup> sequence around codon 217. The introduced Y217C missense mutation and the silent mutation creating an additional BanII restriction site are highlighted (asterisks). (<bold>G</bold>) WT and <italic>Trp53</italic><sup>Y217C/Y217C</sup> (YC/YC) MEFs express similar p53 mRNA levels. Total RNA was extracted, then p53 mRNAs were quantified by real-time qPCR, normalized to control mRNAs and the amount in WT cells was assigned the value of 1. Means + SEM (n=3) are shown. Primer sequences are listed in <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Labeled files for gels and blots in <xref ref-type="fig" rid="fig1">Figure 1B, C, D, and E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-102434-fig1-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Raw and unedited gels and blots for <xref ref-type="fig" rid="fig1">Figure 1B, C, D, and E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-102434-fig1-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102434-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Protein sequence alignment showing homology between mouse p53 Tyrosine 217 and human p53 Tyrosine 220.</title><p>Portions of the DNA-binding domains from the mouse (residues 208–228) and human (residues 211–231) p53 proteins are shown, with identical residues in bold, and mouse Tyrosine 217 and human Tyrosine 220 in red.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102434-fig1-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Deficient p53-dependent stress responses in <italic>Trp53</italic><sup>YC/YC</sup> cells</title><p>We used western blots to analyze protein extracts from <italic>Trp53</italic><sup>+/+</sup>, <italic>Trp53</italic><sup>+/-</sup>, <italic>Trp53</italic><sup>+/YC</sup>, <italic>Trp53</italic><sup>YC/YC</sup>, and <italic>Trp53</italic><sup>-/-</sup> MEFs, unstressed or treated with Nutlin, an antagonist of Mdm2, the E3 ubiquitin ligase for p53 (<xref ref-type="bibr" rid="bib85">Vassilev et al., 2004</xref>). Results indicated a high increase in p53 abundance in untreated and Nutlin-treated <italic>Trp53</italic><sup>YC/YC</sup> MEFs and a moderate increase in untreated and Nutlin-treated <italic>Trp53</italic><sup>+/YC</sup> MEFs, compared to WT cells (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Protein levels for p21 and Mdm2, the products of two classical p53 target genes, appeared similar in <italic>Trp53</italic><sup>+/+</sup> and <italic>Trp53</italic><sup>+/YC</sup> MEFs, and were undetectable or markedly decreased in <italic>Trp53</italic><sup>YC/YC</sup> and <italic>Trp53</italic><sup>-/-</sup> MEFs (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Accordingly, p53<sup>Y217C</sup> appeared unable to transactivate the <italic>Cdkn1a</italic> (alias <italic>p21</italic>) and <italic>Mdm2</italic> genes or to bind their promoters (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). The fractionation of cells before or after treatment with doxorubicin, a clastogenic drug, indicated that p53<sup>WT</sup> accumulated in the nucleoplasm and chromatin fractions in response to DNA damage, whereas p53<sup>Y217C</sup> appeared mostly cytoplasmic in both untreated and doxorubicin-treated cells, and undetectable or barely detectable in chromatin fractions (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Furthermore, when Nutlin-treated MEFs were analyzed by immunofluorescence, p53<sup>WT</sup> was only detected in nuclei, whereas p53<sup>Y217C</sup> could be observed in nuclear and cytoplasmic compartments (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). We next analyzed two well-known p53-mediated responses to DNA damage, i.e., cell cycle arrest in MEFs and apoptosis in thymocytes (<xref ref-type="bibr" rid="bib45">Kastan et al., 1992</xref>; <xref ref-type="bibr" rid="bib56">Lowe et al., 1993</xref>). WT MEFs exposed to increasing doses of γ-irradiation (3 or 12 Gy) exhibited significant increases in G1/S ratios, whereas G1/S ratios were similar before or after irradiation in <italic>Trp53</italic><sup>YC/YC</sup> and <italic>Trp53</italic><sup>-/-</sup> MEFs (<xref ref-type="fig" rid="fig2">Figure 2E</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Furthermore, thymocytes recovered from irradiated WT mice underwent a massive apoptotic response, with an almost threefold increase in apoptotic cells after a 10 Gy irradiation. By contrast, no increase in apoptotic cells was observable upon irradiation in the thymi from <italic>Trp53</italic><sup>YC/YC</sup> mice, and apoptotic thymocytes were equally rare in irradiated <italic>Trp53</italic><sup>YC/YC</sup> and <italic>Trp</italic>53<sup>-/-</sup> mice (<xref ref-type="fig" rid="fig2">Figure 2F</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). Together, these results indicated that the p53<sup>Y217C</sup> mutation altered the abundance and intracellular distribution of the p53 protein, associated with a decrease in DNA-bound protein, and that p53<sup>Y217C</sup> had completely lost the ability to induce cell cycle arrest and apoptosis upon DNA damage.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title><italic>Trp53</italic><sup>YC/YC</sup> cells exhibit alterations in p53 abundance and subcellular localization, defective responses to DNA damage, and increased chromosomal instability.</title><p>(<bold>A</bold>) Increased p53 protein levels in <italic>Trp53</italic><sup>YC/YC</sup> and <italic>Trp53</italic><sup>+/YC</sup> mouse embryonic fibroblasts (MEFs). MEFs of the indicated genotypes were treated or not with 10 μM Nutlin 3a for 24 hr, then protein extracts were immunoblotted with antibodies against Mdm2, p53, p21, and actin. (<bold>B</bold>) The transactivation of classical p53 target genes <italic>Cdkn1a</italic> and <italic>Mdm2</italic> is impaired in <italic>Trp53</italic><sup>YC/YC</sup> cells. Wildtype (WT), <italic>Trp53</italic><sup>YC/YC</sup>, and <italic>Trp53</italic><sup>-/-</sup> MEFs were treated as in (<bold>A</bold>), then (top) mRNAs were quantified in five to six independent experiments using real-time PCR, with results normalized to control mRNAs and mean RNA amounts in unstressed WT cells assigned a value of 1; or (bottom) ChIP assays were performed at the <italic>Cdkn1a</italic> and <italic>Mdm2</italic> promoters in two to three independent experiments with an antibody against p53 or rabbit IgG as a negative control. Immunoprecipitates were quantified using real-time PCR, normalized to data over an irrelevant region, and the amount in unstressed WT cells was assigned a value of 1. Error bars: SEM. (<bold>C</bold>) Assessment of p53<sup>WT</sup> and p53<sup>Y217C</sup> subcellular localization by cellular fractionation. WT and <italic>Trp53</italic><sup>YC/YC</sup> MEFs were treated or not with 1 μΜ doxorubicin (Doxo) for 24 hr, submitted to cellular fractionation, then protein extracts were immunoblotted with antibodies against p53 or the fraction controls Tubulin for cytoplasm (Cp.), Nup98 for nucleoplasm (Np.), and histone H3 for chromatin (χin). (<bold>D</bold>) Assessment of p53<sup>WT</sup> and p53<sup>Y217C</sup> subcellular localization by immunofluorescence. WT, <italic>Trp53</italic><sup>YC/YC</sup> and <italic>Trp53</italic><sup>-/-</sup> MEFs were treated with 10 μM Nutlin 3a for 24 hr, then stained with antibodies against p53 (red) or actin (green) and DNA was counterstained with DAPI (blue). (<bold>E</bold>) Absence of a cell cycle arrest response in <italic>Trp53</italic><sup>YC/YC</sup> MEFs. Asynchronous cell populations of <italic>Trp53</italic><sup>+/+</sup>, <italic>Trp53</italic><sup>YC/YC</sup>, and <italic>Trp53</italic><sup>-/-</sup> MEFs were analyzed 24 hr after 0, 3, or 12 Gy γ-irradiation. Means + SEM from three independent experiments. (<bold>F</bold>) Absence of a p53-dependent apoptotic response in <italic>Trp53</italic><sup>YC/YC</sup> thymocytes. Age-matched mice of the indicated genotypes were left untreated or submitted to 10 Gy whole-body γ-irradiation then sacrificed after 4 hr and their thymocytes were stained with Annexin V-FITC and analyzed by FACS. Means + SEM from two independent experiments. (<bold>G</bold>) Increased chromosomal instability in <italic>Trp53</italic><sup>YC/YC</sup> fibroblasts. Metaphase spreads were prepared from WT, <italic>Trp53</italic><sup>YC/YC</sup>, and <italic>Trp53</italic><sup>-/-</sup> MEFs at passage 4, then aberrant metaphases (with chromosome breaks, radial chromosomes, or double-minute chromosome [DMs]) were scored. Left: distribution of aberrant metaphases. Data from 110 WT, 97 <italic>Trp53</italic><sup>YC/YC</sup>, or 119 <italic>Trp53</italic><sup>-/-</sup> complete diploid metaphases, independently observed by two experimenters. Right: examples of two aberrant <italic>Trp53</italic><sup>YC/YC</sup> metaphases: one with a DM, a chromosome break (Br) and a radial chromosome (R), the other with multiple DMs. Enlargements of regions of interest are presented between the two metaphases. Scale bars (<bold>D, G</bold>): 5 μm. ***p&lt;0.001, **p&lt;0.01, *p&lt;0.05, °p=0.09, ns: non-significant by Student’s t (<bold>B, E, F</bold>) or Fisher’s (<bold>G</bold>) tests.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Labeled files for gels and blots in <xref ref-type="fig" rid="fig2">Figure 2A and C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-102434-fig2-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Raw and unedited gels and blots for <xref ref-type="fig" rid="fig2">Figure 2A and C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-102434-fig2-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102434-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Cell cycle arrest responses of <italic>Trp53</italic><sup>+/+</sup>, <italic>Trp53</italic><sup>YC/YC</sup>, and <italic>Trp53</italic><sup>-/-</sup> mouse embryonic fibroblasts (MEFs).</title><p>Asynchronous MEFs were exposed to 0–12 Gy γ-irradiation, then after 24 hr cells were labeled with BrdU for 1 hr and analyzed by FACS. A typical experiment for cells of each genotype and condition is shown, with % cells in G1, S, or G2/M mentioned in each panel.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102434-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Apoptotic responses of <italic>Trp53</italic><sup>+/+</sup>, <italic>Trp53</italic><sup>-/-</sup>, and <italic>Trp53</italic><sup>YC/YC</sup> thymocytes.</title><p>Mice were γ-irradiated (or not) and their thymocytes were recovered and analyzed by FACS after Annexin V-FITC staining. A typical experiment for cells of each genotype and condition is shown. Numbers indicate % cells either alive (live), early apoptotic (early), or mid to late apoptotic (mid + late).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102434-fig2-figsupp2-v2.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Comparison of stress responses in wildtype (WT), <italic>Trp53</italic><sup>+/YC</sup>, and <italic>Trp53</italic><sup>+/-</sup> cells.</title><p>(<bold>A</bold>) Transactivation of the classical p53 target genes <italic>Cdkn1a</italic> (alias <italic>p21</italic>), <italic>Mdm2,</italic> and <italic>Pmaip1</italic> (alias <italic>Noxa</italic>) in response to Nutlin or Doxorubicin. WT, <italic>Trp53</italic><sup>+/YC</sup>, and <italic>Trp53</italic><sup>+/-</sup> mouse embryonic fibroblasts (MEFs) were treated or not with 10 μM Nutlin 3a (Nut) or 1 μM Doxorubicin (Doxo) for 24 hr, then mRNAs were quantified in ≥4 independent experiments using real-time PCR, with results normalized to control mRNAs and mean RNA amounts in unstressed WT cells assigned a value of 1. Means + SEM are shown. For each condition and gene, a dominant-negative effect (DNE) would lead to significant decrease in transactivation in <italic>Trp53</italic><sup>+/YC</sup> MEFs compared to both WT and <italic>Trp53</italic><sup>+/-</sup> MEFs, a result that was not observed. (<bold>B</bold>) Cell cycle arrest responses to γ-irradiation. Asynchronous cell populations of WT, <italic>Trp53</italic><sup>+/YC</sup>, and <italic>Trp53</italic><sup>+/-</sup> MEFs were analyzed 24 hr after 0, 3, or 12 Gy γ-irradiation. Means + SEM from three independent experiments. The comparison of cells submitted to identical irradiation doses revealed similar arrest responses in cells of all genotypes. (<bold>C</bold>) Apoptotic responses to γ-irradiation. WT, <italic>Trp53</italic><sup>+/YC</sup>, and <italic>Trp53</italic><sup>+/-</sup> MEFs age-matched mice were left untreated or submitted to 10 Gy whole-body γ-irradiation, then sacrificed after 4 hr and their thymocytes were stained with Annexin V-FITC and analyzed by FACS. Means + SEM from two independent experiments. The percentage of apoptotic cells was significantly higher in irradiated WT thymocytes compared to irradiated <italic>Trp53</italic><sup>+/YC</sup> or <italic>Trp53</italic><sup>+/-</sup> cells, whereas <italic>Trp53</italic><sup>+/YC</sup> and <italic>Trp53</italic><sup>+/-</sup> cells were not significantly different. **p&lt;0.01, *p&lt;0.05, ns: non-significant by Student’s t-test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102434-fig2-figsupp3-v2.tif"/></fig></fig-group></sec><sec id="s2-3"><title>Increased chromosomal instability in <italic>Trp53</italic><sup>YC/YC</sup> cells</title><p>We next searched for evidence, at the cellular level, of potential DNE or GOF for the p53<sup>Y217C</sup> mutant. Little if any difference in the transactivation of canonical p53 target genes was observed between WT, <italic>Trp53</italic><sup>+/YC</sup>, and <italic>Trp53</italic><sup>+/-</sup> cells treated with Nutlin or Doxorubicin (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3A</xref>), and <italic>Trp53</italic><sup>+/YC</sup> and <italic>Trp53</italic><sup>+/-</sup> cells exhibited similar cell cycle arrest or apoptotic responses to γ-irradiation (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3B and C</xref>), suggesting little or no DNE in response to various stresses.</p><p>On the opposite, we obtained clear evidence of a GOF for the p53<sup>Y217C</sup> mutant. Two p53 mutants (p53<sup>G245D</sup> and p53<sup>R273H</sup>) were recently proposed to promote tumorigenesis by predisposing cells to chromosomal instability (<xref ref-type="bibr" rid="bib97">Zhao et al., 2024</xref>), which led us to compare the frequency of chromosome rearrangements in WT, <italic>Trp53</italic><sup>YC/YC</sup>, and <italic>Trp</italic>53<sup>-/-</sup> primary MEFs. We searched for chromosome breaks, radial chromosomes, or double-minute chromosomes in preparations of MEFs treated with the anti-mitotic nocodazole for metaphase enrichment. The three categories of chromosome rearrangements were more frequently observed in <italic>Trp53</italic><sup>YC/YC</sup> MEFs than in <italic>Trp</italic>53<sup>-/-</sup> or WT cells (<xref ref-type="fig" rid="fig2">Figure 2G</xref>), indicating a GOF that promotes chromosomal instability.</p></sec><sec id="s2-4"><title>Impact of p53<sup>Y217C</sup> on mouse development</title><p>We next determined the impact of the p53<sup>Y217C</sup> mutation in vivo, by comparing mouse cohorts generated from intercrosses of heterozygous <italic>Trp53</italic><sup>+/-</sup> or <italic>Trp53</italic><sup>+/YC</sup> mice resulting from ≥5 backcrosses to the C57BL/6J background. Intercrosses of <italic>Trp53</italic><sup>+/-</sup> mice are known to yield a reduced proportion of <italic>Trp53</italic><sup>-/-</sup> mice, that is mainly due to defects in neural tube closure causing exencephaly in a fraction of <italic>Trp53</italic><sup>-/-</sup> female embryos (<xref ref-type="bibr" rid="bib4">Armstrong et al., 1995</xref>; <xref ref-type="bibr" rid="bib72">Sah et al., 1995</xref>), and, to a lesser extent, to lung dysfunction affecting a fraction of <italic>Trp53</italic><sup>-/-</sup> neonates (<xref ref-type="bibr" rid="bib80">Tateossian et al., 2015</xref>). At weaning (on the 21st day postpartum or P21), we observed one <italic>Trp53</italic><sup>-/-</sup> female mouse for 3.5 <italic>Trp53</italic><sup>-/-</sup> males from <italic>Trp53</italic><sup>+/-</sup> intercrosses, an underrepresentation of females consistent with frequencies reported in earlier studies (<xref ref-type="bibr" rid="bib4">Armstrong et al., 1995</xref>; <xref ref-type="bibr" rid="bib72">Sah et al., 1995</xref>). Strikingly, the underrepresentation of weaned females was even more acute for <italic>Trp53</italic><sup>YC/YC</sup> mice, with only one <italic>Trp53</italic><sup>YC/YC</sup> female for 19 <italic>Trp53</italic><sup>YC/YC</sup> males from <italic>Trp53</italic><sup>+/YC</sup> intercrosses (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). We next analyzed <italic>Trp53</italic><sup>YC/YC</sup> embryos generated from heterozygous intercrosses or from heterozygous-homozygous (<italic>Trp53</italic><sup>+/YC</sup> × <italic>Trp53</italic><sup>YC/YC</sup>) crosses, at embryonic days E12.5-E16.5. An underrepresentation of <italic>Trp53</italic><sup>YC/YC</sup> female embryos was not observed, but 11/26 (42%) female embryos exhibited developmental abnormalities, including 10 with exencephaly, whereas all the male embryos appeared normal (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Importantly, the frequency of <italic>Trp53</italic><sup>YC/YC</sup> female embryos with exencephaly (38.5%) was much higher than the reported frequency (0–8%) of <italic>Trp53</italic><sup>-/-</sup> female embryos with exencephaly of C57BL/6J x 129/Sv genetic background (<xref ref-type="bibr" rid="bib18">Donehower et al., 1992</xref>; <xref ref-type="bibr" rid="bib72">Sah et al., 1995</xref>), suggesting a stronger effect of the p53<sup>Y217C</sup> mutant on female embryonic development.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title><italic>Trp53</italic><sup>YC/YC</sup> mice exhibit female-specific perinatal lethality.</title><p>(<bold>A</bold>) Distribution of weaned mice obtained from <italic>Trp53</italic><sup>+/-</sup> or <italic>Trp53</italic><sup>+/YC</sup> intercrosses. Obs: observed numbers of mice at weaning (P21); exp: expected numbers assuming a Mendelian distribution without sex distortion; f/m: observed female/male ratios. Consistent with previous reports, the observed distribution of weaned mice from <italic>Trp53</italic><sup>+/-</sup> intercrosses did not conform to values expected for a Mendelian distribution without sex distortion (U=5; χ<sup>2</sup>=16.31&gt;15.09), indicating a significant deficit in female <italic>Trp53</italic><sup>-/-</sup> mice (top). The distribution of weaned mice from <italic>Trp53</italic><sup>+/YC</sup> intercrosses diverged even more from values for a Mendelian distribution without sex distortion (U=5; χ<sup>2</sup>=104.23&gt;15.09), due to a striking deficit in female <italic>Trp53</italic><sup>YC/YC</sup> mice (bottom). Differences between the frequencies of <italic>Trp53</italic><sup>YC/YC</sup> (4/677) and <italic>Trp53</italic><sup>-/-</sup> (8/196) females in the progeny, or between the female to male ratios for <italic>Trp53</italic><sup>YC/YC</sup> (4/75) and <italic>Trp53</italic><sup>-/-</sup> (8/28) animals, are statistically significant (p=0.0012 and p=0.0087 in Fisher’s tests, respectively). (<bold>B</bold>) Exencephaly is frequently observed in p53<sup>YC/YC</sup> female embryos. Top: the distribution of E12.5–16.5 embryos from heterozygous (<italic>Trp53</italic><sup>+/YC</sup>) intercrosses or heterozygous-homozygous (<italic>Trp53</italic><sup>+/YC</sup> × <italic>Trp53</italic><sup>YC/YC</sup>) crosses is shown. f or m exenc.: number of female or male embryos with exencephaly; o.a.: embryos with other abnormalities. Below, examples of female <italic>Trp53</italic><sup>YC/YC</sup> embryos at E12.5, E13.5, and E16.5 exhibiting exencephaly (arrows) are each shown (center) together with a normal embryo from the same litter (bottom). Scale bars : 1 mm. (<bold>C</bold>) Distribution of mice at birth from the indicated crosses. Of note, out of five <italic>Trp53</italic><sup>YC/YC</sup> females observed at birth, only one remained alive at weaning age. Thus, the female/male ratio for weaned <italic>Trp53</italic><sup>YC/YC</sup> animals from these crosses was 1/22, a ratio similar to the one observed in A (4/75).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102434-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Evidence of aberrant chromosome X inactivation in <italic>Trp53</italic><sup>YC/YC</sup> and <italic>Trp53</italic><sup>-/-</sup> female embryos.</title><p>The expression of <italic>Xist</italic> and three X-linked genes (<italic>Maob</italic>, <italic>Usp9x,</italic> and <italic>Pls3</italic>) was quantified in neurospheres from two <italic>Trp53</italic><sup>+/+</sup>, five <italic>Trp53</italic><sup>YC/YC</sup>, and three <italic>Trp53</italic><sup>-/-</sup> female embryos by using real-time PCR, with results normalized to control mRNAs and mean RNA amounts in wildtype (WT) neurospheres assigned a value of 1. Means + SEM are shown. *p&lt;0.05, °p=0.09, ns: non-significant by Student’s t-tests.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102434-fig3-figsupp1-v2.tif"/></fig></fig-group><p>In <italic>Trp53</italic><sup>-/-</sup> female mice, exencephaly was previously correlated with stochastic aberrant X chromosome inactivation, with a decreased expression of <italic>Xist</italic> and an increase in bi-allelic expression of X-linked genes including <italic>Maob</italic>, <italic>Pls3,</italic> and <italic>Usp9x</italic> (<xref ref-type="bibr" rid="bib15">Delbridge et al., 2019</xref>). We prepared neurospheres from <italic>Trp53</italic><sup>+/+</sup>, <italic>Trp53</italic><sup>-/-</sup>, and <italic>Trp53</italic><sup>YC/YC</sup> female embryos and quantified mRNAs for these genes in neurospheres. Compared to neurospheres from WT animals, <italic>Trp53</italic><sup>YC/YC</sup> and <italic>Trp53</italic><sup>-/-</sup> neurospheres exhibited an apparent decrease in <italic>Xist</italic> expression and significantly higher levels of <italic>Maob</italic>, <italic>Pls3,</italic> and <italic>Usp9x</italic> (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Thus, as for female <italic>Trp53</italic><sup>-/-</sup> mice, aberrant chromosome X inactivation may contribute to the underrepresentation of <italic>Trp53</italic><sup>YC/YC</sup> female mice. Of note however, defects in chromosome X inactivation did not appear more pronounced in <italic>Trp53</italic><sup>YC/YC</sup> neurospheres than in <italic>Trp53</italic><sup>-/-</sup> neurospheres.</p><p>To further analyze the impact of the p53<sup>Y217C</sup> mutation during development, we also determined its potential effect in embryos lacking Mdm2 or Mdm4, two major p53 regulators. The embryonic lethality resulting from Mdm2 or Mdm4 loss is rescued by a concomitant p53 deficiency (<xref ref-type="bibr" rid="bib6">Bardot et al., 2015</xref>; <xref ref-type="bibr" rid="bib25">Finch et al., 2002</xref>; <xref ref-type="bibr" rid="bib42">Jones et al., 1995</xref>; <xref ref-type="bibr" rid="bib60">Migliorini et al., 2002</xref>; <xref ref-type="bibr" rid="bib61">Montes de Oca Luna et al., 1995</xref>; <xref ref-type="bibr" rid="bib64">Parant et al., 2001</xref>). This provides a powerful assay for analyzing the functionality of p53 mutant alleles (<xref ref-type="bibr" rid="bib6">Bardot et al., 2015</xref>; <xref ref-type="bibr" rid="bib39">Iwakuma et al., 2004</xref>; <xref ref-type="bibr" rid="bib57">Marine et al., 2006</xref>; <xref ref-type="bibr" rid="bib82">Toledo et al., 2006</xref>). We identified <italic>Mdm2</italic><sup>-/-</sup> <italic>Trp53</italic><sup>YC/YC</sup> and <italic>Mdm4</italic><sup>-/-</sup> <italic>Trp53</italic><sup>YC/YC</sup> viable mice of both sexes, consistent with a major loss of canonical WT p53 activities in the p53<sup>Y217C</sup> mutant (<xref ref-type="table" rid="table1">Table 1</xref>). Of note, in these experiments we mated <italic>Mdm4</italic><sup>+/-</sup> <italic>Trp53</italic><sup>+/YC</sup> mice with <italic>Mdm4</italic><sup>+/-</sup> <italic>Trp53</italic><sup>YC/YC</sup> mice, or <italic>Mdm2</italic><sup>+/-</sup> <italic>Trp53</italic><sup>+/YC</sup> mice with either <italic>Mdm2</italic><sup>-/-</sup> <italic>Trp53</italic><sup>YC/YC</sup> or <italic>Mdm2</italic><sup>+/-</sup> <italic>Trp53</italic><sup>YC/YC</sup> animals, to analyze the progeny at weaning. No <italic>Trp53</italic><sup>YC/YC</sup> female mouse was recovered from these crosses, whereas 14 <italic>Trp53</italic><sup>YC/YC</sup> males were obtained, again demonstrating a striking deficit in <italic>Trp53</italic><sup>YC/YC</sup> females at weaning. Among animals lacking one or two copies of either <italic>Mdm2</italic> or <italic>Mdm4</italic>, we also observed a deficit in <italic>Trp53</italic><sup>YC/YC</sup> weaned females. However, the female to male ratio for <italic>Trp53</italic><sup>YC/YC</sup> animals appeared markedly increased in genetic backgrounds with <italic>Mdm4</italic> haploinsufficiency (4/15) or loss (1/6), but only marginally increased (if at all) in genetic backgrounds with <italic>Mdm2</italic> haploinsufficiency (1/11) or loss (1/11). This suggested that altering the levels of p53 inhibitors, particularly Mdm4, might improve the survival of <italic>Trp53</italic><sup>YC/YC</sup> females (<xref ref-type="table" rid="table1">Table 1</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Viability of Mdm2 or Mdm4 loss in a <italic>Trp53</italic><sup>YC/YC</sup> background.</title><p>Mouse distributions from the indicated crosses were determined at weaning. As for <italic>Trp53</italic><sup>+/YC</sup> intercrosses, these crosses yielded a deficit in weaned <italic>Trp53</italic><sup>YC/YC</sup> females compared to <italic>Trp53</italic><sup>YC/YC</sup> males (4/75 from <italic>Trp53</italic><sup>+/YC</sup> intercrosses [<xref ref-type="fig" rid="fig3">Figure 3A</xref>]; 0/9 from crosses between <italic>Mdm4</italic><sup>+/-</sup> <italic>Trp53</italic><sup>+/YC</sup> and <italic>Mdm4</italic><sup>+/-</sup> <italic>Trp53</italic><sup>YC/YC</sup> mice; and 0/5 from mating <italic>Mdm2</italic><sup>+/-</sup> <italic>Trp53</italic><sup>+/YC</sup> mice with <italic>Mdm2</italic><sup>+/-</sup> <italic>Trp53</italic><sup>YC/YC</sup> or <italic>Mdm2</italic><sup>-/-</sup> <italic>Trp53</italic><sup>YC/YC</sup> animals). <italic>Trp53</italic><sup>YC/YC</sup> females over <italic>Mdm4</italic> or <italic>Mdm2</italic> deficient or haploinsufficient backgrounds were also less frequent than their male counterparts, but the female/male ratio for <italic>Trp53</italic><sup>YC/YC</sup> mice over a <italic>Mdm4</italic><sup>+/-</sup> background (4/15) was significantly increased (p=0.04 when 4/75 and 4/15 ratios are compared in a Fisher’s test). Whether or not the female/male ratios for <italic>Trp53</italic><sup>YC/YC</sup> mice were significantly increased over <italic>Mdm4</italic><sup>-/-</sup> (1/6), <italic>Mdm2</italic><sup>-/-</sup> (1/11), or <italic>Mdm2</italic><sup>+/-</sup> (1/11) backgrounds remained uncertain due to limited animal numbers.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"><italic>Mdm4</italic><sup>+/-</sup><italic>Trp53</italic><sup>YC/YC</sup> × <italic>Mdm4</italic><sup>+/-</sup> <italic>Trp53</italic><sup>+/YC</sup></th><th align="left" valign="bottom">Nr. females</th><th align="left" valign="bottom">Nr. males</th><th align="left" valign="bottom">Sex ratio (f/m)</th><th align="left" valign="bottom">Total</th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic>Mdm4</italic><sup>+/+</sup><italic>Trp53</italic><sup>+/YC</sup></td><td align="left" valign="bottom">8</td><td align="left" valign="bottom">11</td><td align="left" valign="bottom">0.73</td><td align="left" valign="bottom">88</td></tr><tr><td align="left" valign="bottom"><italic>Mdm4</italic><sup>+/+</sup><italic>Trp53</italic><sup>YC/YC</sup></td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">9</td><td align="left" valign="bottom">0.00</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Mdm4</italic><sup>+/-</sup><italic>Trp53</italic><sup>+/YC</sup></td><td align="left" valign="bottom">15</td><td align="left" valign="bottom">19</td><td align="left" valign="bottom">0.79</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Mdm4</italic><sup>+/-</sup><italic>Trp53</italic><sup>YC/YC</sup></td><td align="left" valign="bottom">4</td><td align="left" valign="bottom">15</td><td align="left" valign="bottom">0.27</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Mdm4</italic><sup>-/-</sup><italic>Trp53</italic><sup>+/YC</sup></td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Mdm4</italic><sup>-/-</sup><italic>Trp53</italic><sup>YC/YC</sup></td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">6</td><td align="left" valign="bottom">0.17</td><td align="left" valign="bottom"/></tr><tr><th align="left" valign="bottom"><italic>Mdm2</italic><sup>+/-</sup><italic>Trp53</italic><sup>YC/YC</sup> × <italic>Mdm2</italic><sup>+/-</sup><italic>Trp53</italic><sup>+/YC</sup>or <italic>Mdm2</italic><sup>-/-</sup> <italic>Trp53</italic><sup>YC/YC</sup> × <italic>Mdm2</italic><sup>+/-</sup><italic>Trp53</italic><sup>+/YC</sup></th><th align="left" valign="bottom">Nr. females</th><th align="left" valign="bottom">Nr. males</th><th align="left" valign="bottom">Sex ratio (f/m)</th><th align="left" valign="bottom">Total</th></tr><tr><td align="left" valign="bottom"><italic>Mdm2</italic><sup>+/+</sup><italic>Trp53</italic><sup>+/YC</sup></td><td align="left" valign="bottom">3</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">63</td></tr><tr><td align="left" valign="bottom"><italic>Mdm2</italic><sup>+/+</sup><italic>Trp53</italic><sup>YC/YC</sup></td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">5</td><td align="left" valign="bottom">0.00</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Mdm2</italic><sup>+/-</sup><italic>Trp53</italic><sup>+/YC</sup></td><td align="left" valign="bottom">16</td><td align="left" valign="bottom">15</td><td align="left" valign="bottom">1.07</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Mdm2</italic><sup>+/-</sup><italic>Trp53</italic><sup>YC/YC</sup></td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">11</td><td align="left" valign="bottom">0.09</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Mdm2</italic><sup>-/-</sup><italic>Trp53</italic><sup>+/YC</sup></td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Mdm2</italic><sup>-/-</sup><italic>Trp53</italic><sup>YC/YC</sup></td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">11</td><td align="left" valign="bottom">0.09</td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><p>The high frequency (42%) of abnormal <italic>Trp53</italic><sup>YC/YC</sup> female embryos at E12.5-E16.5 could only partially account for the acute deficit in <italic>Trp53</italic><sup>YC/YC</sup> females observed at weaning, suggesting either embryonic abnormalities undetectable macroscopically, or that a fraction of <italic>Trp53</italic><sup>YC/YC</sup> females died later in development or postpartum. We performed additional crosses to analyze female to male ratios at postpartum day 0 or 1 (P0-P1) and observed 20 females for 18 males for <italic>Trp53</italic><sup>+/+</sup> animals, but only 5 females for 22 males for <italic>Trp53</italic><sup>YC/YC</sup> animals (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Furthermore, only one of these <italic>Trp53</italic><sup>YC/YC</sup> females reached weaning age, and the four other neonates died before P2. Altogether, these data led to conclude that the p53<sup>Y217C</sup> mutation caused female-specific developmental abnormalities at a higher penetrance than a null allele, leading to a perinatal (late embryonic or early postpartum) lethality for most homozygous mutant females.</p><p>Interestingly, we observed that <italic>Trp</italic>53<sup>YC/YC</sup> males were fertile and included them in some of our crosses to generate homozygous mutants at higher frequencies (<xref ref-type="fig" rid="fig3">Figure 3B and C</xref>). By contrast, we were able to mate two <italic>Trp53</italic><sup>YC/YC</sup> adult females with a <italic>Trp53</italic><sup>+/YC</sup> male, and both got pregnant but had to be euthanized due to complications while giving birth. In both cases, extended labor (&gt;24 hr) was the main sign of dystocia (<xref ref-type="table" rid="table2">Table 2</xref>). These observations suggest that, even for the rare <italic>Trp53</italic><sup>YC/YC</sup> females able to reach adulthood, the p53<sup>Y217C</sup> mutation caused pathological traits not observed in <italic>Trp53</italic><sup>-/-</sup> females, because the loss of p53 was not previously reported to cause dystocia (<xref ref-type="bibr" rid="bib21">Embree-Ku and Boekelheide, 2002</xref>; <xref ref-type="bibr" rid="bib30">Guimond et al., 1996</xref>; <xref ref-type="bibr" rid="bib36">Hu et al., 2007</xref>). Together, our data indicated that the p53<sup>Y217C</sup> mutation not only abolished canonical p53 activities, but also conferred additional effects compromising female perinatal viability or parturition.</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Evidence of dystocia in pregnant <italic>Trp53</italic><sup>YC/YC</sup> females.</title><p>Results of the mating of two (a and b) <italic>Trp53</italic><sup>YC/YC</sup> females (F) with a <italic>Trp53</italic><sup>+/YC</sup> male (M) are shown. Both females were rapidly pregnant after encountering a male, but had to be sacrificed due to extended labor and pain during their first (female a) or third (female b) delivery.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">F <italic>Trp53</italic><sup>YC/YC</sup> amated with M <italic>Trp53</italic><sup>+/YC</sup></th><th align="left" valign="bottom"/></tr></thead><tbody><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>Litter 1</bold></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">1 pup born 23 days after mating was initiated, found dead (partially eaten)</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">24 hr later, mother is still in labor</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">48 hr later, another pup found dead in cage, the mother appeared in pain and was sacrificed</td></tr><tr><th align="left" valign="bottom">F <italic>Trp53</italic><sup>YC/YC</sup> bmated with M <italic>Trp53</italic><sup><bold>+/YC</bold></sup></th><th align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>Litter 1</bold></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">2 pups born 24 days after mating was initiated: 1 found dead, 1 alive (F <italic>Trp53</italic><sup>+/YC</sup>)</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>Litter 2</bold></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">4 pups, all alive: 1 F <italic>Trp53</italic><sup>+/YC</sup>, 3 M <italic>Trp53</italic><sup>+/YC</sup></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>Litter 3</bold></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">After extended labor (24 hr) pup fragments were found in cage, the mother in pain was sacrificed with pups still inside the womb</td></tr></tbody></table></table-wrap></sec><sec id="s2-5"><title>Impact of p53<sup>Y217C</sup> on tumorigenesis</title><p>We next analyzed the impact of the p53<sup>Y217C</sup> mutation on the onset and spectrum of spontaneous tumors in mice. We first compared <italic>Trp53</italic><sup>+/YC</sup>, <italic>Trp53</italic><sup>+/-</sup>, and <italic>Trp53</italic><sup>+/+</sup> mouse cohorts for 2 years. <italic>Trp53</italic><sup>+/YC</sup> and <italic>Trp53</italic><sup>+/-</sup> cohorts exhibited similar spontaneous tumor onset and spectrum, with most mice developing sarcomas during their second year of life (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Thus, at least for tumors arising spontaneously, the p53<sup>Y217C</sup> mutant protein did not appear to exert a DNE over the WT p53 protein.</p><p>We next compared <italic>Trp53</italic><sup>YC/YC</sup> and <italic>Trp53</italic><sup>-/-</sup> mouse cohorts. Because of the difficulty to generate <italic>Trp53</italic><sup>YC/YC</sup> females, we restricted our comparison to males, to avoid potential biases that might result from different sex ratios. All <italic>Trp53</italic><sup>-/-</sup> mice are known to die in less than 1 year, from thymic lymphomas in most cases, or more rarely from sarcomas (<xref ref-type="bibr" rid="bib18">Donehower et al., 1992</xref>; <xref ref-type="bibr" rid="bib40">Jacks et al., 1994</xref>). <italic>Trp53</italic><sup>YC/YC</sup> males died faster than their <italic>Trp53</italic><sup>-/-</sup> counterparts: all the <italic>Trp53</italic><sup>YC/YC</sup> males were dead by the age of 7 months, whereas more than 20% of the <italic>Trp53</italic><sup>-/-</sup> males were still alive at that age (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Furthermore, most <italic>Trp53</italic><sup>-/-</sup> and <italic>Trp53</italic><sup>YC/YC</sup> mice died from thymic lymphomas, but histological analysis of tumor organs revealed that the lymphomas in <italic>Trp53</italic><sup>YC/YC</sup> males were more aggressive and invasive, with sites of metastases notably including the lungs, spleen, liver, or kidneys (<xref ref-type="fig" rid="fig4">Figure 4B and C</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). Thus, the p53<sup>Y217C</sup> mutation not only abolished canonical tumor suppressive activities but also apparently conferred oncogenic properties to the encoded protein. Consistent with this, when we performed an RNA-seq analysis of thymi from 8-week-old <italic>Trp53</italic><sup>+/+</sup>, <italic>Trp53</italic><sup>-/-</sup>, and <italic>Trp53</italic><sup>YC/YC</sup> males, 81.5% of the 717 differentially expressed genes indicated an LOF in the p53<sup>Y217C</sup> mutant, but genes suggesting a GOF or an SOF were also observed (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3A</xref> and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Of note, among the differentially expressed genes corresponding to an LOF in the p53<sup>Y217C</sup> mutant were <italic>Bbc3</italic> (alias <italic>Puma</italic>), <italic>Cdkn1a</italic> (alias <italic>p21</italic>), and <italic>Zmat3</italic> (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3B</xref>), three p53 target genes known to play major roles in p53-mediated tumor suppression (<xref ref-type="bibr" rid="bib13">Brennan et al., 2024</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Oncogenic effects of the mutant protein in <italic>Trp53</italic><sup>YC/YC</sup> male mice.</title><p>(<bold>A–B</bold>) In homozygous males, p53<sup>Y217C</sup> leads to accelerated tumor-induced death (<bold>A</bold>), and aggressive metastatic tumors (<bold>B</bold>); n=cohort size. (<bold>C</bold>) Hematoxylin and eosin (H&amp;E) staining of sections from the lung (top) and spleen (bottom) of <italic>Trp53</italic><sup>-/-</sup> and <italic>Trp53</italic><sup>YC/YC</sup> male mice, showing metastases in <italic>Trp53</italic><sup>YC/YC</sup> animals. Normal organ structures are shown, with ‘A’ indicating pulmonary alveoli, and ‘WP’ and ‘RP’ standing for splenic white and red pulp, respectively. In the lung section of the <italic>Trp53</italic><sup>YC/YC</sup> mouse, the rectangle indicates a lymphoma area. In the spleen section of the <italic>Trp53</italic><sup>YC/YC</sup> mouse, the typical splenic structures are absent due to massive tissue homogenization of the spleen by lymphoma cells.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102434-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title><italic>Trp53</italic><sup>+/YC</sup> and <italic>Trp53</italic><sup>+/-</sup> mice exhibit similar tumor onset and spectra.</title><p>No significant difference was observed between heterozygous <italic>Trp53</italic><sup>+/-</sup> and <italic>Trp53</italic><sup>+/YC</sup> mice, neither in spontaneous tumor onset and survival (<bold>A</bold>), nor in tumor spectra (<bold>B</bold>); n=cohort size. Mice of both sexes were included in this study.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102434-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Example of a <italic>Trp53</italic><sup>YC/YC</sup> mouse with a thymic lymphoma and lymphomatous infiltrates in the liver and kidney.</title><p>Hematoxylin and eosin (H&amp;E) staining of sections from the thymus (top), liver (middle), and kidney (bottom) of a <italic>Trp53</italic><sup>YC/YC</sup> male mouse, showing tumor lymphocytes (TL) in the thymus and lymphocyte infiltrates (LI) in the liver and kidney, near blood vessels (BV). Hepatocytes (H), kidney tubules (TB), and a glomerulus (G) are also indicated.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102434-fig4-figsupp2-v2.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>RNA-seq analysis from the thymi of 8-week-old <italic>Trp53</italic><sup>+/+</sup>, <italic>Trp53</italic><sup>YC/YC</sup>, and <italic>Trp53</italic><sup>-/-</sup> male mice.</title><p>(<bold>A</bold>) Heat-map plot, with 717 differentially expressed genes suggestive of a loss of function (LOF), a separation of function (SOF), or a gain of function (GOF) for the p53<sup>Y217C</sup> mutant, ranked according to log<sub>2</sub> fold change (n=number of genes). (<bold>B</bold>) Evidence of LOF in <italic>Trp53</italic><sup>YC/YC</sup> cells for genes encoding Puma, p21, and Zmat3. Data from three mice per genotype. Means + SEM are shown. ***p&lt;0.001, **p&lt;0.01, *p&lt;0.05, °p=0.07, ns: non-significant by Student’s t-tests.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102434-fig4-figsupp3-v2.tif"/></fig></fig-group><p>We next performed a comparative analysis focusing on <italic>Trp53</italic><sup>YC/YC</sup> and <italic>Trp53</italic><sup>-/-</sup> thymi, which revealed 192 differentially expressed genes (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref> and <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). An analysis of these data with GOrilla, the Gene Ontology enRIchment anaLysis and visuaLizAtion tool (<xref ref-type="bibr" rid="bib20">Eden et al., 2009</xref>), indicated that 141 of these genes were associated with at least one gene ontology (GO) term, and revealed a significant enrichment for genes associated with white blood cell chemotaxis/migration and inflammation (<xref ref-type="fig" rid="fig5">Figure 5C</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Among these genes were notably <italic>Ccl17</italic>, <italic>Ccl9</italic>, <italic>Ccr3</italic>, <italic>Cxcl10</italic>, <italic>S100a8,</italic> and <italic>S100a9</italic>, six genes associated each with 10–15 GO terms related to white blood cell behavior and inflammation (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). We next used RT-qPCR to quantify the expression of these genes in thymi from 8-week-old <italic>Trp53</italic><sup>+/+</sup>, <italic>Trp53</italic><sup>YC/YC</sup>, and <italic>Trp53</italic><sup>-/-</sup> male mice. Their expression was significantly increased in <italic>Trp53</italic><sup>YC/YC</sup> thymic cells compared to <italic>Trp53</italic><sup>-/-</sup>, or to both <italic>Trp53</italic><sup>+/+</sup> and <italic>Trp53</italic><sup>-/-</sup> cells, consistent with GOF/SOF effects in the p53<sup>Y217C</sup> mutant (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). We also compared the transcriptomes of <italic>Trp53</italic><sup>YC/YC</sup> and <italic>Trp53</italic><sup>-/-</sup> thymocytes by gene set enrichment analysis (GSEA) (<xref ref-type="bibr" rid="bib79">Subramanian et al., 2005</xref>). We found 13 gene sets significantly enriched in <italic>Trp53</italic><sup>YC/YC</sup> cells with normalized enrichment scores (NES)&gt;2, among which three (‘antimicrobial peptides’, ‘chemokine receptors bind chemokines’, and ‘defensins’) were related to immunity (<xref ref-type="fig" rid="fig5">Figure 5E</xref>, <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2A</xref>), consistent with an inflammatory response associated with the p53<sup>Y217C</sup> mutant. Other enriched gene sets notably included five sets (‘electron transport chain’, ‘respiratory electron transport ATP synthesis by chemiosmotic coupling and heat production by uncoupling proteins’, ‘mitochondrial translation’, ‘respiratory electron transport’, and ‘oxidative phosphorylation’) related to mitochondria function, and three sets (‘deposition of new CENPA-containing nucleosomes at the centromere’, ‘arginine methyltransferases methylate histone arginines’, and ‘PRC2 methylates histones and DNA’) related to chromatin plasticity (<xref ref-type="fig" rid="fig5">Figure 5E</xref>, <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2B and C</xref>). These gene sets, differentially expressed between <italic>Trp53</italic><sup>YC/YC</sup> and <italic>Trp53</italic><sup>-/-</sup> cells, might contribute to accelerated tumorigenesis in <italic>Trp53</italic><sup>YC/YC</sup> mice, given the reported impact of inflammation, metabolism changes, and epigenetic plasticity on cancer evolution (<xref ref-type="bibr" rid="bib23">Feinberg et al., 2006</xref>; <xref ref-type="bibr" rid="bib29">Greten and Grivennikov, 2019</xref>; <xref ref-type="bibr" rid="bib50">Kroemer and Pouyssegur, 2008</xref>). Furthermore, the hotspot mutants p53<sup>G245D</sup> or p53<sup>R273H</sup> were recently proposed to promote tumor progression by inducing non-canonical nuclear factor kappa light chain enhancer of activated B cell (NC-NF-κB) signaling (<xref ref-type="bibr" rid="bib97">Zhao et al., 2024</xref>). In <italic>Trp53</italic><sup>YC/YC</sup> cells, one gene set related to NC-NF-κB (‘Dectin 1-mediated non-canonical NF-κB signaling’) was significantly enriched and two other NF-κB-related gene sets were also potentially enriched (<xref ref-type="fig" rid="fig5">Figure 5F</xref>, <xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Evidence of inflammation in <italic>Trp53</italic><sup>YC/YC</sup> mice.</title><p>(<bold>A–B</bold>) RNA-seq analysis of thymi from <italic>Trp53</italic><sup>YC/YC</sup> (n=3) and <italic>Trp53</italic><sup>-/-</sup> (n=3) 8-week-old male mice. Volcano plot (<bold>A</bold>), with differentially expressed genes (DEGs), downregulated (blue) or upregulated (red) in <italic>Trp53</italic><sup>YC/YC</sup> cells. Unsupervised clustering heat-map plot (<bold>B</bold>), with 192 DEGs ranked according to log<sub>2</sub> fold changes. (<bold>C</bold>) Gene ontology (GO) analysis of DEGs. Out of 192 DEGs, 141 are associated with at least one GO term, according to the Gene Ontology enRIchment anaLysis and visuaLizAtion tool (GOrilla). For each GO term, enrichment was calculated by comparing with the full list of 19,759 genes associated with a GO term, and results are presented here with a color scale according to p-value of enrichment. This analysis mainly revealed an enrichment for genes associated with white blood cell chemotaxis/migration and inflammation, as shown here. Complete results of the analysis are presented in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>. (<bold>D</bold>) RT-qPCR analysis of the indicated genes in thymi from 8-week-old <italic>Trp53</italic><sup>+/+</sup>, <italic>Trp53</italic><sup>YC/YC</sup>, and <italic>Trp53</italic><sup>-/-</sup> male mice. Means + SEM (n=3 per genotype). ***p&lt;0.001, **p&lt;0.01, *p&lt;0.05, °p&lt;0.075 by Student’s t-test. (<bold>E</bold>) Gene set enrichment analysis (GSEA) of transcriptomes from <italic>Trp53</italic><sup>YC/YC</sup> and <italic>Trp53</italic><sup>-/-</sup> thymic cells. GSEA identified 13 gene sets enriched in <italic>Trp53</italic><sup>YC/YC</sup> cells with normalized enrichment scores (NES)&gt;2. Nominal p-values (NOM p-val) and false discovery rate q-values (FDR q-val) are indicated. (<bold>F</bold>) GSEA provides evidence of increased NC-NF-κB signaling in <italic>Trp53</italic><sup>YC/YC</sup> male thymocytes. Results are presented as in (E). (<bold>G</bold>) Supformin (LCC-12), an anti-inflammatory molecule, increases the female to male ratio in <italic>Trp53</italic><sup>YC/YC</sup> weaned pups. <italic>Trp53</italic><sup>+/YC</sup> females were mated with <italic>Trp53</italic><sup>YC/YC</sup> males, then oral gavage of pregnant females with 5 mg/kg supformin was performed on the 10th and 11th days post-coitum, and their progeny was genotyped at weaning. The female to male (f/m) ratio for <italic>Trp53</italic><sup>YC/YC</sup> weaned pups that were exposed to supformin in utero (+) was compared to the f/m ratios for <italic>Trp53</italic><sup>-/-</sup> or <italic>Trp53</italic><sup>YC/YC</sup> weaned pups never exposed to supformin (-). Exposure to supformin led to a fivefold increase in the proportion of <italic>Trp53</italic><sup>YC/YC</sup> weaned females. **p&lt;0.01, °p=0.056, ns: non-significant by Fisher’s test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102434-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Gene ontology (GO) analysis of differentially expressed genes (DEGs).</title><p>The 192 DEGs between <italic>Trp53</italic><sup>-/-</sup> and <italic>Trp53</italic><sup>YC/YC</sup> thymocytes (<xref ref-type="fig" rid="fig5">Figure 5A</xref>) were analyzed with the Gene Ontology enRIchment anaLysis and visuaLizAtion tool (GOrilla). Out of 192 genes, 141 were associated with a GO term. For each GO term, enrichment was calculated by comparing with the full list of 19,759 genes associated with a GO term. For example, genes with GO term #0071621 (granulocyte chemotaxis) represent 79/19,759 genes associated with a GO term, but 8/141 of the identified DEGs, which represents a 14.19-fold enrichment.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102434-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Gene set enrichment analysis (GSEA) of transcriptomes from <italic>Trp53</italic><sup>Y217C/Y217C</sup> (Y220C) and <italic>Trp53</italic><sup>-/-</sup> (KO) thymic cells: examples of GSEA enrichment plots.</title><p>Examples of GSEA enrichment plots indicating differences in immune responses (<bold>A</bold>), mitochondrial function (<bold>B</bold>), and chromatin plasticity (<bold>C</bold>) are shown.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102434-fig5-figsupp2-v2.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>Gene set enrichment analysis (GSEA) enrichment plot showing increased NC-NF-κB signaling in <italic>Trp53</italic><sup>YC/YC</sup> cells.</title><p>Transcriptomes from <italic>Trp53</italic><sup>Y217C/Y217C</sup> (Y220C) and <italic>Trp53</italic><sup>-/-</sup> (KO) thymic cells were compared by GSEA.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102434-fig5-figsupp3-v2.tif"/></fig></fig-group></sec><sec id="s2-6"><title>Reducing inflammation may rescue a fraction of female <italic>Trp53</italic><sup>YC/YC</sup> embryos</title><p>Our data indicated that inflammation correlated with accelerated tumorigenesis in <italic>Trp53</italic><sup>YC/YC</sup> male mice. Interestingly, inflammation was previously proposed to promote neural tube defects or embryonic death in a few mouse models (<xref ref-type="bibr" rid="bib52">Lian et al., 2004</xref>; <xref ref-type="bibr" rid="bib59">McNairn et al., 2019</xref>; <xref ref-type="bibr" rid="bib95">Zhao et al., 2013</xref>). Furthermore <italic>CD44</italic>, encoding a cell-surface glycoprotein that drives inflammation and cancer progression (<xref ref-type="bibr" rid="bib77">Solier et al., 2023</xref>), was recently identified as a key gene for the diagnosis and early detection of open neural tube defects (<xref ref-type="bibr" rid="bib44">Karthik et al., 2022</xref>). Together, these data led us to hypothesize that, at least in a fraction of <italic>Trp53</italic><sup>YC/YC</sup> females, neural tube defects might result from inflammation. To test this hypothesis, we mated <italic>Trp53</italic><sup>+/YC</sup> female mice with <italic>Trp53</italic><sup>YC/YC</sup> males, then administered supformin to pregnant females by oral gavage. Supformin (LCC-12), a potent inhibitor of the CD44-copper signaling pathway, was shown to reduce inflammation in vivo (<xref ref-type="bibr" rid="bib77">Solier et al., 2023</xref>). Without any treatment, our previous crosses (<xref ref-type="fig" rid="fig3">Figure 3</xref> and <xref ref-type="table" rid="table1">Table 1</xref>) collectively yielded a female to male ratio of 0.045 for <italic>Trp53</italic><sup>YC/YC</sup> weaned mice (f/m=5/111 [4+1+ 0+0]/[75+22+ 9+5]), significantly different from the ratio of 0.29 (f/m=8/28) for <italic>Trp53</italic><sup>-/-</sup> weaned animals. By contrast, in the progeny of supformin-treated pregnant mice we observed a fivefold increase in the female to male ratio for <italic>Trp53</italic><sup>YC/YC</sup> weaned animals, to reach a value of 0.23 (f/m=3/13) indistinguishable from the ratio in <italic>Trp53</italic><sup>-/-</sup> weaned animals from untreated mice (<xref ref-type="fig" rid="fig5">Figure 5G</xref> and <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). This result suggests that reducing inflammation in developing <italic>Trp53</italic><sup>YC/YC</sup> female embryos may increase their viability.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this report, we generated a mouse model with a <italic>Trp53</italic><sup>Y217C</sup> allele, the murine equivalent of the human hotspot mutant <italic>TP53</italic><sup>Y220C</sup>. The analysis of this mouse model indicated that the p53<sup>Y217C</sup> mutation leads to the loss of many canonical WT p53 activities, notably the capacity to transactivate target genes important for tumor suppression (e.g. <italic>Bbc3</italic>, <italic>Cdkn1a,</italic> and <italic>Zmat3</italic>). The fact that p53<sup>Y217C</sup> can rescue the embryonic lethality caused by a deficiency in Mdm2 or Mdm4 is also consistent with a major loss of canonical WT p53 functions (LOF) in this mutant. These findings are consistent with the notion that hotspot p53 mutants cause a complete or near complete LOF (<xref ref-type="bibr" rid="bib26">Funk et al., 2025</xref>).</p><p>In addition, our analyses provide evidence that the p53<sup>Y217C</sup> mutation exhibits oncogenic effects. The possibility that a mutant p53 might acquire oncogenic functions was first suggested over 30 years ago (<xref ref-type="bibr" rid="bib17">Dittmer et al., 1993</xref>), but this notion became controversial in recent years. Indeed, studies of a few p53 mutants in human acute myeloid leukemia and a mouse model of B cell lymphoma indicated that their increased tumorigenicity might result from DNE rather than GOF, and a recent study further suggested that the putative GOF of many p53 mutants would not be required to sustain the expansion of tumors (<xref ref-type="bibr" rid="bib5">Aubrey et al., 2018</xref>; <xref ref-type="bibr" rid="bib11">Boettcher et al., 2019</xref>; <xref ref-type="bibr" rid="bib90">Wang et al., 2024</xref>). Here, however, we observed accelerated tumorigenesis in <italic>Trp53</italic><sup>YC/YC</sup> mice, but did not observe any evidence of DNE for spontaneous tumorigenesis in <italic>Trp53</italic><sup>+/YC</sup> animals. Importantly, the fact that p53<sup>Y217C</sup> did not exhibit a DNE over the WT protein is consistent with the report that Li-Fraumeni patients carrying an heterozygous <italic>TP53</italic><sup>Y220C</sup> mutation display a similar age of cancer onset than Li-Fraumeni patients with an heterozygous non-sense <italic>TP53</italic> mutation (<xref ref-type="bibr" rid="bib92">Xu et al., 2014</xref>). Furthermore, our evidence of an oncogenic GOF leading to aggressive metastatic tumors in <italic>Trp53</italic><sup>YC/YC</sup> male mice is consistent with the oncogenic GOF attributed to p53<sup>Y220C</sup> in male patients with glioblastoma (<xref ref-type="bibr" rid="bib70">Rockwell et al., 2021</xref>) or with experiments suggesting that p53<sup>Y220C</sup> expression in p53-null cells, or its overexpression in MCF-10A cells, may increase their migratory or invasive capacities (<xref ref-type="bibr" rid="bib63">Pal et al., 2023</xref>; <xref ref-type="bibr" rid="bib98">Zhou et al., 2022</xref>).</p><p>Our transcriptomic analyses suggested that the p53<sup>Y217C</sup> mutant might accelerate tumorigenesis by promoting inflammation, a hallmark of cancer (<xref ref-type="bibr" rid="bib33">Hanahan, 2022</xref>) previously associated with a few other hotspot p53 mutants with oncogenic GOF (<xref ref-type="bibr" rid="bib1">Agupitan et al., 2020</xref>; <xref ref-type="bibr" rid="bib8">Behring et al., 2019</xref>; <xref ref-type="bibr" rid="bib32">Ham et al., 2019</xref>; <xref ref-type="bibr" rid="bib97">Zhao et al., 2024</xref>). Interestingly, the GSEA comparison of transcriptomes from <italic>Trp53</italic><sup>YC/YC</sup> and <italic>Trp</italic>53<sup>-/-</sup> male thymic cells indicated differences related to inflammation and chemokine signaling, but also to mitochondria function and chromatin plasticity, and a link between inflammation, mitochondrial copper, and epigenetic plasticity was recently demonstrated (<xref ref-type="bibr" rid="bib77">Solier et al., 2023</xref>). Furthermore, the p53<sup>G245D</sup> or p53<sup>R273H</sup> mutants were proposed to accelerate tumorigenesis by promoting a chromosomal instability that would activate NC-NF-κB signaling and promote tumor cell metastasis (<xref ref-type="bibr" rid="bib97">Zhao et al., 2024</xref>). Here, we observed increased chromosomal instability in <italic>Trp53</italic><sup>YC/YC</sup> fibroblasts, increased NC-NF-κB and inflammation-related signaling in <italic>Trp53</italic><sup>YC/YC</sup> thymocytes, and increased tumor metastasis in <italic>Trp53</italic><sup>YC/YC</sup> mice compared to their <italic>Trp53<sup>-/-</sup></italic> counterparts. These data suggest that similar mechanisms might underlie the oncogenic properties of the p53<sup>Y217C</sup>, p53<sup>G245D</sup>, and p53<sup>R273H</sup> mutants.</p><p>A striking and unexpected effect of the p53<sup>Y217C</sup> mutation was its severe impact on the perinatal viability of female mice, which led to observe only four <italic>Trp53</italic><sup>YC/YC</sup> females for 75 <italic>Trp53</italic><sup>YC/YC</sup> males at weaning from heterozygous intercrosses, or five <italic>Trp53</italic><sup>YC/YC</sup> females for 111 <italic>Trp53</italic><sup>YC/YC</sup> males when all weaned animals from relevant crosses were considered. The perinatal lethality of <italic>Trp53</italic><sup>YC/YC</sup> females correlated with a high frequency (38.5%) of exencephalic females at E12.5–16.5 embryonic ages. By comparison, the female to male ratio at weaning was 8/28 for <italic>Trp53</italic><sup>-/-</sup> mice, and only 0–8% of exencephalic female <italic>Trp53</italic><sup>-/-</sup> embryos were reported in similar genetic backgrounds (<xref ref-type="bibr" rid="bib4">Armstrong et al., 1995</xref>; <xref ref-type="bibr" rid="bib18">Donehower et al., 1992</xref>; <xref ref-type="bibr" rid="bib72">Sah et al., 1995</xref>). These observations provide evidence of teratogenic effects for the p53<sup>Y217C</sup> mutant protein. Three other mouse p53 models were previously found to cause exencephaly at a higher frequency than a p53 null allele: <italic>Trp53</italic><sup>NLS1</sup>, with three mutations at residues 316–318 affecting a nuclear localization signal and leading to a predominantly cytoplasmic localization of p53<sup>NLS1</sup> in most cells (<xref ref-type="bibr" rid="bib69">Regeling et al., 2011</xref>); <italic>Trp53</italic><sup>N236S</sup>, a mouse model of <italic>TP53</italic><sup>N239S</sup>, a recurrent but uncommon mutant in human cancers (<xref ref-type="bibr" rid="bib96">Zhao et al., 2019</xref>); and <italic>Bim</italic><sup>+/-</sup> <italic>Trp53</italic><sup>-/-</sup> mice, combining p53 loss with an haploinsufficiency in the cytoplasmic proapoptotic regulator Bim/Bcl2l11 (<xref ref-type="bibr" rid="bib15">Delbridge et al., 2019</xref>). The female-specific lethality of <italic>Trp53</italic><sup>N236S</sup> mice was proposed to result from increased <italic>Xist</italic> expression, whereas a decrease in <italic>Xist</italic> expression was observed in <italic>Bim</italic><sup>+/-</sup> <italic>Trp53</italic><sup>-/-</sup> mice, suggesting distinct causes for neural tube defects (<xref ref-type="bibr" rid="bib15">Delbridge et al., 2019</xref>; <xref ref-type="bibr" rid="bib96">Zhao et al., 2019</xref>). We observed decreased <italic>Xist</italic> expression and an increased expression of X-linked genes in neurospheres from <italic>Trp53</italic><sup>YC/YC</sup> females compared to WT females, whereas these genes were expressed at similar levels in neurospheres from <italic>Trp53</italic><sup>YC/YC</sup> and <italic>Trp53</italic><sup>-/-</sup> females. These results are not consistent with the mechanism proposed for exencephaly in the <italic>Trp53</italic><sup>N236S</sup> mouse model, but might rather reflect a p53 LOF in <italic>Trp53</italic><sup>YC/YC</sup> embryos. In addition, the analyses of the <italic>Trp53</italic><sup>NLS1</sup> and <italic>Bim</italic><sup>+/-</sup> <italic>Trp53</italic><sup>-/-</sup> mouse models make it tempting to speculate that, in female <italic>Trp53</italic><sup>YC/YC</sup> embryos, the abundance of p53<sup>Y217C</sup> in the cytoplasm might perturb mitochondria function (<xref ref-type="bibr" rid="bib10">Blandino et al., 2020</xref>) to further promote neural tube closure defects. Consistent with this possibility, p53 mutant proteins accumulating in the cytoplasm were reported to inhibit autophagy (<xref ref-type="bibr" rid="bib62">Morselli et al., 2008</xref>), a key determinant for mitochondrial integrity (<xref ref-type="bibr" rid="bib68">Rambold and Lippincott-Schwartz, 2011</xref>), and autophagy impairment may promote neural tube defects (<xref ref-type="bibr" rid="bib24">Fimia et al., 2007</xref>; <xref ref-type="bibr" rid="bib93">Ye et al., 2020</xref>).</p><p>Importantly, our data suggest that common mechanisms might contribute to the oncogenic effects accelerating tumorigenesis in <italic>Trp53</italic><sup>YC/YC</sup> males and the teratogenic effects causing the perinatal lethality of many <italic>Trp53</italic><sup>YC/YC</sup> females. Indeed, the RNA-seq analysis of male thymocytes indicated that inflammation likely promotes oncogenesis in <italic>Trp53</italic><sup>YC/YC</sup> males, and the administration of the anti-inflammatory drug supformin to pregnant mice increased the ratio of <italic>Trp53</italic><sup>YC/YC</sup> weaned females in their progeny. Thus, the low female/male ratio observed for <italic>Trp53</italic><sup>YC/YC</sup> weaned animals would likely result not only from aberrant X chromosome inactivation in female embryos as in <italic>Trp53</italic><sup>-/-</sup> animals (<xref ref-type="bibr" rid="bib15">Delbridge et al., 2019</xref>), but also from inflammation. Presumably, a higher level of chromosomal instability in <italic>Trp53</italic><sup>YC/YC</sup> cells might promote inflammation in <italic>Trp53</italic><sup>YC/YC</sup> embryos (<xref ref-type="bibr" rid="bib71">Rodier et al., 2009</xref>), and this might be more detrimental to females because <italic>Trp53</italic><sup>YC/YC</sup> males would be protected by the anti-inflammatory effects of androgens (<xref ref-type="bibr" rid="bib2">Ainslie et al., 2024</xref>; <xref ref-type="bibr" rid="bib9">Bianchi, 2019</xref>; <xref ref-type="bibr" rid="bib59">McNairn et al., 2019</xref>). Of note, we also observed that decreased Mdm4 levels increased the female/male ratio in <italic>Trp53</italic><sup>YC/YC</sup> weaned mice. Because MDM4 overexpression was shown to promote genome instability and inflammation in cells independently of p53 (<xref ref-type="bibr" rid="bib14">Carrillo et al., 2015</xref>; <xref ref-type="bibr" rid="bib54">Liu et al., 2024</xref>), it is tempting to speculate that, as for supformin-treated mice, the improved survival of <italic>Trp53</italic><sup>YC/YC</sup> female embryos in an Mdm4<sup>+/-</sup> background might result from decreased inflammation. Interestingly, in the offspring of human pregnancies at risk of early preterm delivery, an interleukin-6 polymorphism was associated with a female-specific susceptibility to adverse neurodevelopmental outcome (<xref ref-type="bibr" rid="bib84">Varner et al., 2020</xref>), suggesting that inflammation may also impact the development of human female embryos. Finally, our mating attempts with <italic>Trp53</italic><sup>YC/YC</sup> mice indicated that <italic>Trp53</italic><sup>YC/YC</sup> pregnant females exhibited dystocia, and parturition is considered to be a finely regulated inflammatory process (<xref ref-type="bibr" rid="bib94">Zhang and Wei, 2021</xref>). Of note, dystocia was not observed in <italic>Trp53</italic><sup>-/-</sup> mice, but was previously reported in pregnant females with a combined deficiency of p53 and FasL (<xref ref-type="bibr" rid="bib21">Embree-Ku and Boekelheide, 2002</xref>). The fact that <italic>Trp53</italic><sup>YC/YC</sup> females shared phenotypic traits with both <italic>Bim</italic><sup>+/-</sup> <italic>Trp53</italic><sup>-/-</sup> mice (neural tube defects) and <italic>FasL</italic><sup>-/-</sup> <italic>Trp53</italic><sup>-/-</sup> mice (dystocia) may seem relevant, because Bim and FasL are both regulators of apoptosis and autophagy that also regulate immune responses (<xref ref-type="bibr" rid="bib76">Sionov et al., 2015</xref>; <xref ref-type="bibr" rid="bib81">Taylor and Ng, 2018</xref>). Altogether, these data suggest that inflammation may cause accelerated tumorigenesis in <italic>Trp53</italic><sup>YC/YC</sup> male mice and contribute to promote neural tube defects in <italic>Trp53</italic><sup>YC/YC</sup> female embryos or dystocia in <italic>Trp53</italic><sup>YC/YC</sup> pregnant females (<xref ref-type="table" rid="table3">Table 3</xref>).</p><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Effects of the <italic>Trp53</italic><sup>Y217C</sup> mutation: a summary.</title><p>The comparison between <italic>Trp53</italic><sup>-/-</sup> and <italic>Trp53</italic><sup>Y217C/Y217C</sup> mice is presented. The phenotypes observed in <italic>Trp53</italic><sup>-/-</sup> male (M) and female (F) mice result from p53 loss of function (LOF), whereas those observed in <italic>Trp53</italic><sup>Y217C/Y217C</sup> mice result from p53 LOF as well as additional effects (gain of function [GOF] in red). The + signs denote the presence of a phenotype. Xi: X chromosome inactivation.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" valign="bottom"><italic>Trp53</italic><sup>-/-</sup> (LOF)</td><td align="left" valign="bottom"><italic>Trp53</italic><sup>Y217C/Y217C</sup> (LOF<styled-content style="color: #D50000;">+</styled-content><styled-content style="color: #D50000;">GOF</styled-content>)</td></tr><tr><td align="left" valign="top">Spontaneous tumors (mostly thymic lymphomas), death in ≤1 year.<break/>++<break/>(M &amp; F)</td><td align="left" valign="top">Spontaneous tumors (mostly thymic lymphomas) <styled-content style="color: #D50000;">with</styled-content><styled-content style="color: #D50000;"> metastases</styled-content>, death in <styled-content style="color: #D50000;">≤</styled-content><styled-content style="color: #D50000;">7</styled-content> <styled-content style="color: #D50000;">months</styled-content><break/>++<styled-content style="color: #D50000;">+</styled-content><break/>(only M were evaluated due to scarcity of F)<styled-content style="color: #D50000;"> inflammation in thymic cells</styled-content></td></tr><tr><td align="left" valign="top">Perinatal lethality<break/>+<break/>(F only: Xi aberrations)</td><td align="left" valign="top">Perinatal lethality <styled-content style="color: #D50000;">increased</styled-content><break/>+<styled-content style="color: #D50000;">++++</styled-content><break/>(F only: Xi aberrations <styled-content style="color: #D50000;">and inflammation</styled-content>)<break/><styled-content style="color: #D50000;">F partial rescue by supformin</styled-content></td></tr><tr><td align="left" valign="top">No dystocia<break/><break/>(pregnant F)</td><td align="left" valign="top"><styled-content style="color: #D50000;">D</styled-content><styled-content style="color: #D50000;">ystocia</styled-content><break/><styled-content style="color: #D50000;">+</styled-content><break/>(pregnant F)</td></tr></tbody></table></table-wrap><p>In conclusion, we generated a mouse model expressing p53<sup>Y217C</sup>, the murine equivalent of human p53<sup>Y220C</sup>, and its analysis revealed that the GOF of a hotspot mutant p53 may not be limited to oncogenic effects. This is an important notion to consider given the ever-expanding functions ascribed to p53 (<xref ref-type="bibr" rid="bib37">Hu, 2009</xref>; <xref ref-type="bibr" rid="bib67">Rakotopare and Toledo, 2023</xref>; <xref ref-type="bibr" rid="bib88">Voskarides and Giannopoulou, 2023</xref>; <xref ref-type="bibr" rid="bib89">Vousden and Lane, 2007</xref>). In addition, our results unveiled the potential relevance of supformin in obstetrics, which deserves further investigation.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Gene (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Trp53</italic></td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">ENSMUSG00000059552</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>, both sexes)</td><td align="left" valign="bottom"><italic>Trp53</italic><sup>Y217C</sup> (<italic>Trp53</italic><sup>YC</sup>)<italic>,</italic> C57Bl/6J</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">‘Targeting in ES cells and genotyping’</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>, females)</td><td align="left" valign="bottom"> <italic>PGK-Cre,</italic> C57Bl/6J</td><td align="left" valign="bottom">Jackson Labs</td><td align="left" valign="bottom">B6.C-Tg(Pgk1-cre)1Lni/CrsJ</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>, both sexes)</td><td align="left" valign="bottom"><italic>Trp53</italic><sup>-</sup><italic>,</italic> C57Bl/6J</td><td align="left" valign="bottom">Jackson Labs</td><td align="left" valign="bottom">B6.129S2-<italic>Trp53</italic><sup>tm1Tyj</sup>/J</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>, both sexes)</td><td align="left" valign="bottom">C57Bl/6J</td><td align="left" valign="bottom">Charles River Labs</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus,</italic> both sexes)</td><td align="left" valign="bottom">WT, <italic>Trp53</italic><sup>+/YC</sup><italic>, Trp53</italic><sup>YC/YC</sup><italic>, Trp53</italic><sup>+/-</sup><italic>, Trp53</italic><sup>-/-</sup> fibroblasts</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Primary fibroblasts from E13.5 embryos</td><td align="left" valign="bottom">‘Cells and cell culture reagents’</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus,</italic> females)</td><td align="left" valign="bottom">WT<italic>, Trp53</italic><sup>YC/YC</sup><italic>, Trp53</italic><sup>-/-</sup> neurospheres</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Neurospheres from E14.5 embryos</td><td align="left" valign="bottom">‘Cells and cell culture reagents’</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">p53 (Rabbit polyclonal)</td><td align="left" valign="bottom">Novocastra</td><td align="left" valign="bottom">Leica NCL-p53-CM5p</td><td align="char" char="." valign="bottom">1/2000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">p53 (Rabbit polyclonal)</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">FL-393 Sc 6243</td><td align="left" valign="bottom">50 μg</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">p53 (Goat polyclonal)</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">AF-1355</td><td align="char" char="." valign="bottom">1/600</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mdm2 (Mouse monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="char" char="hyphen" valign="bottom">4B-2</td><td align="char" char="." valign="bottom">1/500</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">p21 (Mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">F-5 sc6246</td><td align="char" char="." valign="bottom">1/200</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Actin (Mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">Actin-HRP sc47778</td><td align="char" char="." valign="bottom">1/5000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Tubulin (Rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab15568</td><td align="char" char="." valign="bottom">1/1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Nup98 (Rat monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab50610</td><td align="char" char="." valign="bottom">1/1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Histone H3 (Rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab1791</td><td align="char" char="." valign="bottom">1/1000</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Trp53 (c)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Primer for genotyping</td><td align="left" valign="bottom"><named-content content-type="sequence">GTGTGTTGGCCATCTCTGTG</named-content>; <xref ref-type="fig" rid="fig1">Figure 1</xref></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Trp53 (d)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Primer for genotyping</td><td align="left" valign="bottom"><named-content content-type="sequence">AACCGGACTCAGCGTCTCTA</named-content>; <xref ref-type="fig" rid="fig1">Figure 1</xref></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Trp53-F</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib22">Fajac et al., 2024</xref></td><td align="left" valign="bottom">qPCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">AAAGGATGCCCATGCTACAGA</named-content>; <xref ref-type="fig" rid="fig1">Figure 1</xref></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Trp53-R</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib22">Fajac et al., 2024</xref></td><td align="left" valign="bottom">qPCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">TCTTGGTCTTCAGGTAGCTGGAG</named-content>; <xref ref-type="fig" rid="fig1">Figure 1</xref></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Ccl17-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">GCTGGTATAAGACCTCAGTGGAGTGT</named-content>; <xref ref-type="fig" rid="fig5">Figure 5</xref></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Ccl17-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">GCTTGCCCTGGACAGTCAGA</named-content>; <xref ref-type="fig" rid="fig5">Figure 5</xref></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Ccl9-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">GCACAGCAAGGGCTTGAAA</named-content>; <xref ref-type="fig" rid="fig5">Figure 5</xref></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Ccl9-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">CAGGCAGCAATCTGAAGAGTCTT</named-content>; <xref ref-type="fig" rid="fig5">Figure 5</xref></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">S100a8-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">TCCTTTGTCAGCTCCGTCTTC</named-content>; <xref ref-type="fig" rid="fig5">Figure 5</xref></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">S100a8-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">GACGGCATTGTCACGAAAGAT</named-content>; <xref ref-type="fig" rid="fig5">Figure 5</xref></td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Superscript IV</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">TF #18090010</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Nucleospin RNA II</td><td align="left" valign="bottom">Macherey-Nagel</td><td align="left" valign="bottom">FS #NZ74095520</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Power SYBR Green</td><td align="left" valign="bottom">Applied Biosystems</td><td align="left" valign="bottom">#4367659</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Supersignal West Femto</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">#34096</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Annexin V-FITC apoptosis staining/ detection kit</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">#Ab14085</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">TruSeq Stranded Total RNA</td><td align="left" valign="bottom">Illumina</td><td align="left" valign="bottom">#20020596</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Nutlin 3a</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">#SML-0580</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Doxorubicin</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">#D1515</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Supformin</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib77">Solier et al., 2023</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">FlowJo</td><td align="left" valign="bottom">Beckton-Dickinson</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_008520">SCR_008520</ext-link></td><td align="char" char="." valign="bottom">10.10</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">featureCounts</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib53">Liao et al., 2014</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">DESeq2 R package</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib55">Love et al., 2014</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GOrilla</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib20">Eden et al., 2009</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GSEA software</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib79">Subramanian et al., 2005</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Prism</td><td align="left" valign="bottom">GraphPad</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_002798">SCR_002798</ext-link></td><td align="char" char="." valign="bottom">5.0</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>LSL-Y217C construct</title><p>We used mouse genomic <italic>Trp53</italic> DNA from previous constructs, containing a portion of intron 1 with a LoxP-Stop-LoxP (LSL) cassette (<xref ref-type="bibr" rid="bib86">Ventura et al., 2007</xref>) in which the puromycin resistance gene was replaced by a neomycin resistance gene (<xref ref-type="bibr" rid="bib75">Simeonova et al., 2013</xref>). The point mutation (A to G) encoding a Tyr to Cys substitution (TAT to TGT) at codon 217, together with a silent mutation nearby creating a Ban II restriction site, were introduced by PCR directed mutagenesis by using primers Y217C-F and Y217C-R (see <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref> for primer sequences). The resulting <italic>Trp53</italic><sup>LSL-Y217C</sup> targeting vector was fully sequenced before use.</p></sec><sec id="s4-2"><title>Targeting in ES cells and genotyping</title><p>129/SvJ ES cells were electroporated with the targeting construct linearized with Not I. Two recombinant clones, identified by long-range PCR and confirmed by internal PCR and Southern blot, were injected into C57BL/6J blastocysts to generate chimeras, and germline transmission was verified by genotyping their offspring. In vivo excision of the LSL cassette was performed by breeding <italic>Trp53</italic><sup>+/LSL-Y217C</sup> male mice with females carrying the PGK-<italic>Cre</italic> transgene (<xref ref-type="bibr" rid="bib51">Lallemand et al., 1998</xref>) and genotyping their offspring. The <italic>Trp53</italic><sup>Y217C</sup> (p53<sup>YC</sup>) mutation was routinely genotyped by PCR using primers c and d (<xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>) followed by BanII digestion. Tumorigenesis studies were performed on mouse cohorts resulting from ≥5 generations of backcrosses with C57BL6/J mice. For all experiments, mice housing and treatment were conducted according to the Institutional Animal Care and Use Committee of the Institut Curie (approved project #03769.02).</p></sec><sec id="s4-3"><title>Cells and cell culture reagents</title><p>MEFs isolated from 13.5-day embryos were cultured in a 5% CO<sub>2</sub> and 3% O<sub>2</sub> incubator, in DMEM GlutaMAX (Gibco), with 15% FBS (Biowest), 100 μM 2-mercaptoethanol (Millipore), 0.01 mM Non-Essential Amino-Acids, and penicillin/streptomycin (Gibco) for ≤6 passages. Cells were irradiated with a Cs γ-irradiator or treated for 24 hr with 10 μM Nutlin 3a (Sigma-Aldrich) or 1 μM Doxorubicin (Sigma-Aldrich). Neurospheres were prepared by isolating neural stem/progenitor cells (NPCs) from the lateral and median ganglionic eminences of E14.5 embryos. NPCs were cultured in a 5% CO<sub>2</sub> incubator, in DMEM/F12 medium (with L-Glutamine, Invitrogen) supplemented with 1% B-27 (Invitrogen), 1% N2 (Invitrogen), 0.3% glucose (Invitrogen), 25 μg/ml insulin (Sigma-Aldrich), 20 ng/ml EGF (PeproTech), 10 ng/ml bFGF (PeproTech), and penicillin/streptomycin (Gibco). Neurospheres were dissociated once a week by Accutase treatment and mechanically, then seeded at 10<sup>6</sup> cells per 6 cm diameter dish. Cell culture supernatants were tested and found negative for mycoplasma contamination.</p></sec><sec id="s4-4"><title>Quantitative RT-PCR</title><p>Total RNA, extracted using NucleoSpin RNA II (Macherey-Nagel), was reverse-transcribed using SuperScript IV (Invitrogen). Real-time quantitative PCRs were performed as previously described (<xref ref-type="bibr" rid="bib74">Simeonova et al., 2012</xref>), on an ABI PRISM 7500 using Power SYBR Green (Applied Biosystems). Primer sequences are reported in <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>.</p></sec><sec id="s4-5"><title>Western blots</title><p>Cells were lysed in RIPA buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 5 mM EDTA, 0.5% deoxycholic acid, 0.1% SDS, 1% NP-40) supplemented with Protease inhibitors cocktail (Roche) and 1 mM PMSF (Sigma). Whole-cell extracts were sonicated three times for 10 s and centrifuged at 13,000 rpm for 30 min to remove cell debris. Protein lysate concentration was determined by BCA assay (Thermo Scientific) and 30 μg of each lysate was fractionated by SDS-PAGE on a 4–12% polyacrylamide gel and transferred onto polyvinylidene difluoride membranes (Amersham). Membranes were incubated with antibodies raised against Mdm2 (MDM2-4B2, Abcam, 1/500), p53 (CM-5, Novocastra, 1/2000), p21 (F5, Santa Cruz Biotechnology, 1/200), and actin (actin-HRP sc47778, Santa Cruz Biotechnology, 1/5000). Chemiluminescence revelation of western blots was achieved with the SuperSignal West Dura (Perbio).</p></sec><sec id="s4-6"><title>ChIP assay</title><p>ChIP analysis was performed as previously described (<xref ref-type="bibr" rid="bib75">Simeonova et al., 2013</xref>). p53-DNA complexes were immunoprecipitated from total extracts by using 50 μg of a polyclonal antibody against p53 (FL-393, Santa Cruz Biotechnology) and 300 μg of sonicated chromatin. Rabbit IgG (Abcam) was used for control precipitation. Quantitative PCR was performed on ABI PRISM 7500. Primer sequences are reported in <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>.</p></sec><sec id="s4-7"><title>Cell fractionation assay</title><p>Cells were lysed in hypotonic lysis buffer (10 mM Tris pH 7.5, 10 mM NaCl, 3 mM MgCl<sub>2</sub>, 0.3% NP-40, 10% glycerol) on ice for 10 min, then centrifuged at 4°C for 3 min at 1000×<italic>g</italic>. The supernatant was recovered as the cytoplasmic fraction, and the pellet was incubated in a modified Wuarin-Schibler buffer (10 mM Tris-HCl pH 7.0, 4 mM EDTA, 0.3 M NaCl, 1 M urea, 1% NP-40) on ice for 5 min, vortexed, incubated on ice for 10 min, then centrifuged at 4°C for 3 min at 1000×<italic>g</italic>. The supernatant was recovered as the nucleoplasmic fraction, and the pellet was washed, then incubated in a nuclear lysis buffer (20 mM Tris pH 7.5, 150 mM KCl, 3 mM MgCl<sub>2</sub>, 0.3% NP-40, 10% glycerol) on ice for 5 min, sonicated, then centrifuged at 13,000 rpm at 4°C and the supernatant was recovered as the chromatin fraction. All buffers were supplemented with Protease inhibitors cocktail (Roche). Cellular fractions were analyzed by western blots with antibodies against p53 (AF-1355, R&amp;D Systems, 1/600), Tubulin (ab15568, Abcam, 1/1000), Nup98 (ab50610, Abcam, 1/1000), and histone H3 (ab1791, Abcam, 1/1000). Chemiluminescence revelation was achieved with SuperSignal West Pico or Femto (Thermo Scientific) and analyzed with a ChemiDoc Imaging System (Bio-Rad). Scans for chemiluminescence were performed, with or without superposed colorimetric scans for molecular weights.</p></sec><sec id="s4-8"><title>Immunofluorescence</title><p>MEFs were cultured on collagen-coated coverslips, treated with 10 μM Nutlin 3a (Sigma-Aldrich) for 24 hr and analyzed. Coverslips were stained with rabbit anti-p53 FL-393 (Santa Cruz Biotechnology, 1/50), mouse anti-actin primary antibody and with Alexa Fluor 647 anti-Rabbit and Alexa Fluor 488 anti-Mouse secondary antibodies (Molecular Probes). DNA was counterstained with DAPI. Images were captured on an epifluorescence microscope using equal exposure times for all images for each fluor.</p></sec><sec id="s4-9"><title>Cell cycle assay</title><p>Log phase cells were irradiated at room temperature with a Cs γ-irradiator at doses of 3 or 12 Gy, incubated for 24 hr, then pulse labeled for 1 hr with BrdU (10 μM), fixed in 70% ethanol, double stained with FITC anti-BrdU and propidium iodide, and analyzed by flow cytometry with a BD Biosciences FACSort and the FlowJo software.</p></sec><sec id="s4-10"><title>Apoptosis assay</title><p>Six- to eight-week-old mice were left untreated or submitted to 10 Gy whole-body γ-irradiation. Mice were sacrificed 4 hr later and thymi were extracted. Thymocytes were recovered by filtration through a 70 μm smash, stained with Annexin V-FITC Apoptosis detection kit (Abcam) and propidium iodide, then analyzed with an LSRII FACS machine. Data were analyzed using FlowJo software.</p></sec><sec id="s4-11"><title>Metaphase spread preparation and analysis</title><p>Primary MEFs (at passage 4 for all genotypes) were treated with 0.1 mM nocodazole for 3 hr to arrest cells in metaphase, then submitted to hypotonic shock (75 mM KCl), fixed in a (3:1) ethanol/acetic acid solution, dropped onto glass slides, then air-dried slides were stained with Giemsa to score for chromosome aberrations. Images were acquired using a Zeiss Axiophot (×63) microscope.</p></sec><sec id="s4-12"><title>Histology</title><p>Organs were fixed in formol 4% for 24 hr, then ethanol 70%, and embedded in paraffin wax. Serial sections of 3 μm were stained as described (<xref ref-type="bibr" rid="bib75">Simeonova et al., 2013</xref>), with hematoxylin and eosin using standard procedures.</p></sec><sec id="s4-13"><title>RNA-seq analysis</title><p>Total RNA was extracted from the thymi of 8-week-old asymptomatic male mice using nucleospin RNA II (Macherey-Nagel). The quality of RNA was checked with Bioanalyzer Agilent 2100 and RNAs with an RNA integrity number (RIN)&gt;7 were retained for further analysis. RNA was depleted from ribosomal RNA, then converted into cDNA libraries using a TruSeq Stranded Total Library preparation kit (Illumina). Paired-end sequencing was performed on an Illumina MiSeq platform. Reads were mapped to the mouse genome version GRCm38 and counted on gene annotation gencode.vM18 with featureCounts (<xref ref-type="bibr" rid="bib53">Liao et al., 2014</xref>). Differentially expressed genes with an adjusted p-value&lt;0.05 were identified using the DESeq2 R package (<xref ref-type="bibr" rid="bib55">Love et al., 2014</xref>).</p></sec><sec id="s4-14"><title>GO analysis</title><p>GO analysis of differentially expressed genes was performed by using the GOrilla (Technion) software as previously described (<xref ref-type="bibr" rid="bib66">Rakotopare et al., 2023</xref>). Enrichment analyses were carried out by comparing the list of 192 differentially expressed genes between <italic>Trp53</italic><sup>YC/YC</sup> and <italic>Trp53</italic><sup>-/-</sup> thymi to the full list of genes (background), with ontology searches for biological processes and default p-value settings (10<sup>−3</sup>).</p></sec><sec id="s4-15"><title>Gene set enrichment analysis</title><p>GSEA was performed by using the GSEA software with canonical pathway gene sets from the Mouse Molecular Signature Database (MSigDB) (<xref ref-type="bibr" rid="bib79">Subramanian et al., 2005</xref>). Gene sets with a false discovery rate (FDR) q-value&lt;0.25 were regarded as potentially relevant. The best candidates, with an FDR q-value&lt;0.01, exhibited NES&gt;1.91 and nominal p-values&lt;0.003.</p></sec><sec id="s4-16"><title>Oral gavage of pregnant females</title><p><italic>Trp53</italic><sup>+/YC</sup> female mice were mated with <italic>Trp53</italic><sup>YC/YC</sup> males, then mice with a vaginal plug on the next day were separated from males and weighted every other day to confirm pregnancy. On the 10th and 11th days post-coitum, pregnant mice received 5 mg/kg of supformin (in a PBS solution) by oral gavage with flexible gauge feeding tubes, then their pups were genotyped at weaning.</p></sec><sec id="s4-17"><title>Statistical analyses</title><p>Unless noted otherwise, we used a Student’s t-test to analyze differences between two groups of values. For the proportions of mice at weaning, the observed mouse count was compared to the expected count according to Mendel’s distribution and a chi-square (χ<sup>2</sup>) test, and a Fisher’s test was applied to compare frequencies of mutant females or female to male ratios. Fisher’s tests were also used to analyze frequencies of chromosome rearrangements in fibroblasts. Survival curves were analyzed with log-rank Mantel-Cox tests. Analyses were performed by using GraphPad Prism, and values of p≤0.05 were considered significant.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Investigation</p></fn><fn fn-type="con" id="con2"><p>Investigation</p></fn><fn fn-type="con" id="con3"><p>Investigation</p></fn><fn fn-type="con" id="con4"><p>Investigation</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Formal analysis</p></fn><fn fn-type="con" id="con7"><p>Resources</p></fn><fn fn-type="con" id="con8"><p>Investigation</p></fn><fn fn-type="con" id="con9"><p>Investigation</p></fn><fn fn-type="con" id="con10"><p>Investigation</p></fn><fn fn-type="con" id="con11"><p>Resources</p></fn><fn fn-type="con" id="con12"><p>Resources</p></fn><fn fn-type="con" id="con13"><p>Formal analysis, Supervision, Investigation, Visualization, Writing – original draft</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Investigation, Visualization, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>For all experiments, mice housing and treatment were conducted according to the Institutional Animal Care and Use Committee of the Institut Curie (approved project #03769.02).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Differentially expressed genes between wildtype (WT), <italic>Trp53</italic><sup>Y217C/Y217C</sup> (YC), and <italic>Trp53</italic><sup>-/-</sup> (KO) thymocytes from age-matched animals.</title><p>Most differentially expressed genes correspond to a loss of function (LOF) in the p53<sup>Y217C</sup> mutant (categories 1 and 2, see <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3A</xref>), but genes corresponding to a separation of function (SOF, categories 3 and 4) or a gain of function (GOF, categories 5 and 6) were also observed.</p></caption><media xlink:href="elife-102434-supp1-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>A DESeq analysis of RNA-seq data from <italic>Trp53</italic><sup>-/-</sup> (KO) and <italic>Trp53</italic><sup>Y217C/Y217C</sup> (YC) thymi revealed 192 differentially expressed genes.</title><p>As shown in <xref ref-type="fig" rid="fig5">Figure 5B</xref>, 107 genes (in bold) were less expressed and 85 genes were more expressed in <italic>Trp53</italic><sup>YC/YC</sup> cells compared to <italic>Trp53</italic><sup>-/-</sup> cells.</p></caption><media xlink:href="elife-102434-supp2-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title><italic>Ccl17</italic>, <italic>Ccl9</italic>, <italic>Ccr3</italic>, <italic>Cxcl10</italic>, <italic>S100a8,</italic> and <italic>S100a9</italic> are associated with gene ontology (GO) terms of white blood cell migration/chemotaxis and inflammation.</title></caption><media xlink:href="elife-102434-supp3-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>Distribution of weaned pups after mating <italic>Trp53</italic><sup>+/YC</sup> females with <italic>Trp53</italic><sup>YC/YC</sup> males and oral gavage of pregnant females with supformin.</title><p>Due to the gavage of pregnant mothers, all the pups born in this experiment were exposed to supformin in utero (SIU+).</p></caption><media xlink:href="elife-102434-supp4-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>Primers used in this study.</title></caption><media xlink:href="elife-102434-supp5-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-102434-mdarchecklist1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>RNA sequencing data have been deposited in the Gene Expression Omnibus (GEO) under the accession code GSE248936. All other data are available within the article and its supplementary information. Materials can be provided by Franck Toledo pending scientific review and a completed material transfer agreement. Requests for materials should be submitted to franck.toledo@sorbonne-universite.fr.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Bardot</surname><given-names>B</given-names></name><name><surname>Toledo</surname><given-names>F</given-names></name><name><surname>Gabriel</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>Thymocytes mRNA profiles of 8 weeks-old p53+/+, p53Y217C/Y217C and p53-/- male mice</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE248936">GSE248936</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>This project was supported by grants attributed to FT, from the Ligue Nationale Contre le Cancer, the Fondation ARC pour la recherche sur le Cancer and the Gefluc. SJ, EE, and JR were PhD fellows of the Ministère de la Recherche, supervised by FT (SJ, JR) or BB (EE). SJ and EE received additional support from the Fondation ARC. MG was paid by European Research Council 875532-Prostator-ERC-2019-PoC attributed to AM. For some experiments, SJ and VV received technical assistance from C Bouyer and R Bourimi. We thank the following members of the Institut Curie platforms: I Grandjean, H Gautier, C Daviaud, M Garcia, D Andreau, M Verlhac, and A Fosse (animal facility); S Baulande and S Lameiras (NGS); M Huerre, A Nicolas, and R Leclere (histopathology); Z Maciorowski, A Viguier, and S Grondin (flow cytometry).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agupitan</surname><given-names>AD</given-names></name><name><surname>Neeson</surname><given-names>P</given-names></name><name><surname>Williams</surname><given-names>S</given-names></name><name><surname>Howitt</surname><given-names>J</given-names></name><name><surname>Haupt</surname><given-names>S</given-names></name><name><surname>Haupt</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>P53: A guardian of immunity becomes its saboteur through mutation</article-title><source>International Journal of Molecular Sciences</source><volume>21</volume><elocation-id>3452</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21103452</pub-id><pub-id pub-id-type="pmid">32414156</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ainslie</surname><given-names>RJ</given-names></name><name><surname>Simitsidellis</surname><given-names>I</given-names></name><name><surname>Kirkwood</surname><given-names>PM</given-names></name><name><surname>Gibson</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>RISING STARS: androgens and immune cell function</article-title><source>The Journal of Endocrinology</source><volume>261</volume><elocation-id>e230398</elocation-id><pub-id pub-id-type="doi">10.1530/JOE-23-0398</pub-id><pub-id pub-id-type="pmid">38579776</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amelio</surname><given-names>I</given-names></name><name><surname>Melino</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Context is everything: extrinsic signalling and gain-of-function p53 mutants</article-title><source>Cell Death Discovery</source><volume>6</volume><elocation-id>16</elocation-id><pub-id pub-id-type="doi">10.1038/s41420-020-0251-x</pub-id><pub-id pub-id-type="pmid">32218993</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>JF</given-names></name><name><surname>Kaufman</surname><given-names>MH</given-names></name><name><surname>Harrison</surname><given-names>DJ</given-names></name><name><surname>Clarke</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>High-frequency developmental abnormalities in p53-deficient mice</article-title><source>Current Biology</source><volume>5</volume><fpage>931</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1016/s0960-9822(95)00183-7</pub-id><pub-id pub-id-type="pmid">7583151</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aubrey</surname><given-names>BJ</given-names></name><name><surname>Janic</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>Lieschke</surname><given-names>EC</given-names></name><name><surname>Diepstraten</surname><given-names>ST</given-names></name><name><surname>Kueh</surname><given-names>AJ</given-names></name><name><surname>Bernardini</surname><given-names>JP</given-names></name><name><surname>Dewson</surname><given-names>G</given-names></name><name><surname>O’Reilly</surname><given-names>LA</given-names></name><name><surname>Whitehead</surname><given-names>L</given-names></name><name><surname>Voss</surname><given-names>AK</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name><name><surname>Strasser</surname><given-names>A</given-names></name><name><surname>Kelly</surname><given-names>GL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mutant TRP53 exerts a target gene-selective dominant-negative effect to drive tumor development</article-title><source>Genes &amp; Development</source><volume>32</volume><fpage>1420</fpage><lpage>1429</lpage><pub-id pub-id-type="doi">10.1101/gad.314286.118</pub-id><pub-id pub-id-type="pmid">30366906</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bardot</surname><given-names>B</given-names></name><name><surname>Bouarich-Bourimi</surname><given-names>R</given-names></name><name><surname>Leemput</surname><given-names>J</given-names></name><name><surname>Lejour</surname><given-names>V</given-names></name><name><surname>Hamon</surname><given-names>A</given-names></name><name><surname>Plancke</surname><given-names>L</given-names></name><name><surname>Jochemsen</surname><given-names>AG</given-names></name><name><surname>Simeonova</surname><given-names>I</given-names></name><name><surname>Fang</surname><given-names>M</given-names></name><name><surname>Toledo</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mice engineered for an obligatory Mdm4 exon skipping express higher levels of the Mdm4-S isoform but exhibit increased p53 activity</article-title><source>Oncogene</source><volume>34</volume><fpage>2943</fpage><lpage>2948</lpage><pub-id pub-id-type="doi">10.1038/onc.2014.230</pub-id><pub-id pub-id-type="pmid">25088193</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beckerman</surname><given-names>R</given-names></name><name><surname>Prives</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Transcriptional regulation by p53</article-title><source>Cold Spring Harb Perspect Biol</source><volume>8</volume><elocation-id>a000935</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a000935</pub-id><pub-id pub-id-type="pmid">20679336</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behring</surname><given-names>M</given-names></name><name><surname>Vazquez</surname><given-names>AI</given-names></name><name><surname>Cui</surname><given-names>X</given-names></name><name><surname>Irvin</surname><given-names>MR</given-names></name><name><surname>Ojesina</surname><given-names>AI</given-names></name><name><surname>Agarwal</surname><given-names>S</given-names></name><name><surname>Manne</surname><given-names>U</given-names></name><name><surname>Shrestha</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Gain of function in somatic TP53 mutations is associated with immune-rich breast tumors and changes in tumor-associated macrophages</article-title><source>Molecular Genetics &amp; Genomic Medicine</source><volume>7</volume><elocation-id>e1001</elocation-id><pub-id pub-id-type="doi">10.1002/mgg3.1001</pub-id><pub-id pub-id-type="pmid">31637877</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bianchi</surname><given-names>VE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The anti-inflammatory effects of testosterone</article-title><source>Journal of the Endocrine Society</source><volume>3</volume><fpage>91</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1210/js.2018-00186</pub-id><pub-id pub-id-type="pmid">30582096</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blandino</surname><given-names>G</given-names></name><name><surname>Valenti</surname><given-names>F</given-names></name><name><surname>Sacconi</surname><given-names>A</given-names></name><name><surname>Di Agostino</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Wild type- and mutant p53 proteins in mitochondrial dysfunction: emerging insights in cancer disease</article-title><source>Seminars in Cell &amp; Developmental Biology</source><volume>98</volume><fpage>105</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2019.05.011</pub-id><pub-id pub-id-type="pmid">31112799</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boettcher</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>PG</given-names></name><name><surname>Sharma</surname><given-names>R</given-names></name><name><surname>McConkey</surname><given-names>M</given-names></name><name><surname>Leventhal</surname><given-names>M</given-names></name><name><surname>Krivtsov</surname><given-names>AV</given-names></name><name><surname>Giacomelli</surname><given-names>AO</given-names></name><name><surname>Wong</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Chao</surname><given-names>S</given-names></name><name><surname>Kurppa</surname><given-names>KJ</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Milenkowic</surname><given-names>K</given-names></name><name><surname>Piccioni</surname><given-names>F</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name><name><surname>Rücker</surname><given-names>FG</given-names></name><name><surname>Flamand</surname><given-names>Y</given-names></name><name><surname>Neuberg</surname><given-names>D</given-names></name><name><surname>Lindsley</surname><given-names>RC</given-names></name><name><surname>Jänne</surname><given-names>PA</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name><name><surname>Döhner</surname><given-names>H</given-names></name><name><surname>Armstrong</surname><given-names>SA</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A dominant-negative effect drives selection of <italic>TP53</italic> missense mutations in myeloid malignancies</article-title><source>Science</source><volume>365</volume><fpage>599</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1126/science.aax3649</pub-id><pub-id pub-id-type="pmid">31395785</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouaoun</surname><given-names>L</given-names></name><name><surname>Sonkin</surname><given-names>D</given-names></name><name><surname>Ardin</surname><given-names>M</given-names></name><name><surname>Hollstein</surname><given-names>M</given-names></name><name><surname>Byrnes</surname><given-names>G</given-names></name><name><surname>Zavadil</surname><given-names>J</given-names></name><name><surname>Olivier</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>TP53 variations in human cancers: new lessons from the iarc tp53 database and genomics data</article-title><source>Human Mutation</source><volume>37</volume><fpage>865</fpage><lpage>876</lpage><pub-id pub-id-type="doi">10.1002/humu.23035</pub-id><pub-id pub-id-type="pmid">27328919</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brennan</surname><given-names>MS</given-names></name><name><surname>Brinkmann</surname><given-names>K</given-names></name><name><surname>Romero Sola</surname><given-names>G</given-names></name><name><surname>Healey</surname><given-names>G</given-names></name><name><surname>Gibson</surname><given-names>L</given-names></name><name><surname>Gangoda</surname><given-names>L</given-names></name><name><surname>Potts</surname><given-names>MA</given-names></name><name><surname>Lieschke</surname><given-names>E</given-names></name><name><surname>Wilcox</surname><given-names>S</given-names></name><name><surname>Strasser</surname><given-names>A</given-names></name><name><surname>Herold</surname><given-names>MJ</given-names></name><name><surname>Janic</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Combined absence of TRP53 target genes ZMAT3, PUMA and p21 cause a high incidence of cancer in mice</article-title><source>Cell Death and Differentiation</source><volume>31</volume><fpage>159</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1038/s41418-023-01250-w</pub-id><pub-id pub-id-type="pmid">38110554</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrillo</surname><given-names>AM</given-names></name><name><surname>Bouska</surname><given-names>A</given-names></name><name><surname>Arrate</surname><given-names>MP</given-names></name><name><surname>Eischen</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mdmx promotes genomic instability independent of p53 and Mdm2</article-title><source>Oncogene</source><volume>34</volume><fpage>846</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1038/onc.2014.27</pub-id><pub-id pub-id-type="pmid">24608433</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delbridge</surname><given-names>ARD</given-names></name><name><surname>Kueh</surname><given-names>AJ</given-names></name><name><surname>Ke</surname><given-names>F</given-names></name><name><surname>Zamudio</surname><given-names>NM</given-names></name><name><surname>El-Saafin</surname><given-names>F</given-names></name><name><surname>Jansz</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>GY</given-names></name><name><surname>Iminitoff</surname><given-names>M</given-names></name><name><surname>Beck</surname><given-names>T</given-names></name><name><surname>Haupt</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>May</surname><given-names>RE</given-names></name><name><surname>Whitehead</surname><given-names>L</given-names></name><name><surname>Tai</surname><given-names>L</given-names></name><name><surname>Chiang</surname><given-names>W</given-names></name><name><surname>Herold</surname><given-names>MJ</given-names></name><name><surname>Haupt</surname><given-names>Y</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name><name><surname>Thomas</surname><given-names>T</given-names></name><name><surname>Blewitt</surname><given-names>ME</given-names></name><name><surname>Strasser</surname><given-names>A</given-names></name><name><surname>Voss</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Loss of p53 causes stochastic aberrant x-chromosome inactivation and female-specific neural tube defects</article-title><source>Cell Reports</source><volume>27</volume><fpage>442</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.03.048</pub-id><pub-id pub-id-type="pmid">30970248</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dibra</surname><given-names>D</given-names></name><name><surname>Xiong</surname><given-names>S</given-names></name><name><surname>Moyer</surname><given-names>SM</given-names></name><name><surname>El-Naggar</surname><given-names>AK</given-names></name><name><surname>Qi</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>X</given-names></name><name><surname>Kong</surname><given-names>EK</given-names></name><name><surname>Korkut</surname><given-names>A</given-names></name><name><surname>Lozano</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivo</article-title><source>Science Advances</source><volume>10</volume><elocation-id>eadk1835</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.adk1835</pub-id><pub-id pub-id-type="pmid">38354236</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dittmer</surname><given-names>D</given-names></name><name><surname>Pati</surname><given-names>S</given-names></name><name><surname>Zambetti</surname><given-names>G</given-names></name><name><surname>Chu</surname><given-names>S</given-names></name><name><surname>Teresky</surname><given-names>AK</given-names></name><name><surname>Moore</surname><given-names>M</given-names></name><name><surname>Finlay</surname><given-names>C</given-names></name><name><surname>Levine</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Gain of function mutations in p53</article-title><source>Nature Genetics</source><volume>4</volume><fpage>42</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1038/ng0593-42</pub-id><pub-id pub-id-type="pmid">8099841</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donehower</surname><given-names>LA</given-names></name><name><surname>Harvey</surname><given-names>M</given-names></name><name><surname>Slagle</surname><given-names>BL</given-names></name><name><surname>McArthur</surname><given-names>MJ</given-names></name><name><surname>Montgomery</surname><given-names>CA</given-names></name><name><surname>Butel</surname><given-names>JS</given-names></name><name><surname>Bradley</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours</article-title><source>Nature</source><volume>356</volume><fpage>215</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1038/356215a0</pub-id><pub-id pub-id-type="pmid">1552940</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumbrava</surname><given-names>EE</given-names></name><name><surname>Johnson</surname><given-names>ML</given-names></name><name><surname>Tolcher</surname><given-names>AW</given-names></name><name><surname>Shapiro</surname><given-names>G</given-names></name><name><surname>Thompson</surname><given-names>JA</given-names></name><name><surname>El-Khoueiry</surname><given-names>AB</given-names></name><name><surname>Vandross</surname><given-names>AL</given-names></name><name><surname>Kummar</surname><given-names>S</given-names></name><name><surname>Parikh</surname><given-names>AR</given-names></name><name><surname>Munster</surname><given-names>PN</given-names></name><name><surname>Daly</surname><given-names>E</given-names></name><name><surname>De Leon</surname><given-names>L</given-names></name><name><surname>Khaddar</surname><given-names>M</given-names></name><name><surname>LeDuke</surname><given-names>K</given-names></name><name><surname>Robell</surname><given-names>K</given-names></name><name><surname>Sheehan</surname><given-names>LI</given-names></name><name><surname>St. Louis</surname><given-names>M</given-names></name><name><surname>Wiebesiek</surname><given-names>A</given-names></name><name><surname>Alland</surname><given-names>L</given-names></name><name><surname>Schram</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation</article-title><source>Journal of Clinical Oncology</source><volume>40</volume><elocation-id>3003</elocation-id><pub-id pub-id-type="doi">10.1200/JCO.2022.40.16_suppl.3003</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eden</surname><given-names>E</given-names></name><name><surname>Navon</surname><given-names>R</given-names></name><name><surname>Steinfeld</surname><given-names>I</given-names></name><name><surname>Lipson</surname><given-names>D</given-names></name><name><surname>Yakhini</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists</article-title><source>BMC Bioinformatics</source><volume>10</volume><elocation-id>48</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-10-48</pub-id><pub-id pub-id-type="pmid">19192299</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Embree-Ku</surname><given-names>M</given-names></name><name><surname>Boekelheide</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Absence of p53 and fasl has sexually dimorphic effects on both development and reproduction</article-title><source>Experimental Biology and Medicine</source><volume>227</volume><fpage>545</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1177/153537020222700720</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fajac</surname><given-names>A</given-names></name><name><surname>Simeonova</surname><given-names>I</given-names></name><name><surname>Leemput</surname><given-names>J</given-names></name><name><surname>Gabriel</surname><given-names>M</given-names></name><name><surname>Morin</surname><given-names>A</given-names></name><name><surname>Lejour</surname><given-names>V</given-names></name><name><surname>Hamon</surname><given-names>A</given-names></name><name><surname>Rakotopare</surname><given-names>J</given-names></name><name><surname>Vaysse-Zinkhöfer</surname><given-names>W</given-names></name><name><surname>Eldawra</surname><given-names>E</given-names></name><name><surname>Pinskaya</surname><given-names>M</given-names></name><name><surname>Morillon</surname><given-names>A</given-names></name><name><surname>Bourdon</surname><given-names>JC</given-names></name><name><surname>Bardot</surname><given-names>B</given-names></name><name><surname>Toledo</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Mutant mice lacking alternatively spliced p53 isoforms unveil <italic>Ackr4</italic> as a male-specific prognostic factor in Myc-driven B-cell lymphomas</article-title><source>eLife</source><volume>13</volume><elocation-id>RP92774</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.92774</pub-id><pub-id pub-id-type="pmid">39298333</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feinberg</surname><given-names>AP</given-names></name><name><surname>Ohlsson</surname><given-names>R</given-names></name><name><surname>Henikoff</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The epigenetic progenitor origin of human cancer</article-title><source>Nature Reviews. Genetics</source><volume>7</volume><fpage>21</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1038/nrg1748</pub-id><pub-id pub-id-type="pmid">16369569</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fimia</surname><given-names>GM</given-names></name><name><surname>Stoykova</surname><given-names>A</given-names></name><name><surname>Romagnoli</surname><given-names>A</given-names></name><name><surname>Giunta</surname><given-names>L</given-names></name><name><surname>Di Bartolomeo</surname><given-names>S</given-names></name><name><surname>Nardacci</surname><given-names>R</given-names></name><name><surname>Corazzari</surname><given-names>M</given-names></name><name><surname>Fuoco</surname><given-names>C</given-names></name><name><surname>Ucar</surname><given-names>A</given-names></name><name><surname>Schwartz</surname><given-names>P</given-names></name><name><surname>Gruss</surname><given-names>P</given-names></name><name><surname>Piacentini</surname><given-names>M</given-names></name><name><surname>Chowdhury</surname><given-names>K</given-names></name><name><surname>Cecconi</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Ambra1 regulates autophagy and development of the nervous system</article-title><source>Nature</source><volume>447</volume><fpage>1121</fpage><lpage>1125</lpage><pub-id pub-id-type="doi">10.1038/nature05925</pub-id><pub-id pub-id-type="pmid">17589504</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finch</surname><given-names>RA</given-names></name><name><surname>Donoviel</surname><given-names>DB</given-names></name><name><surname>Potter</surname><given-names>D</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Fan</surname><given-names>A</given-names></name><name><surname>Freed</surname><given-names>DD</given-names></name><name><surname>Wang</surname><given-names>CY</given-names></name><name><surname>Zambrowicz</surname><given-names>BP</given-names></name><name><surname>Ramirez-Solis</surname><given-names>R</given-names></name><name><surname>Sands</surname><given-names>AT</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>mdmx is a negative regulator of p53 activity in vivo</article-title><source>Cancer Research</source><volume>62</volume><fpage>3221</fpage><lpage>3225</lpage><pub-id pub-id-type="pmid">12036937</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Funk</surname><given-names>JS</given-names></name><name><surname>Klimovich</surname><given-names>M</given-names></name><name><surname>Drangenstein</surname><given-names>D</given-names></name><name><surname>Pielhoop</surname><given-names>O</given-names></name><name><surname>Hunold</surname><given-names>P</given-names></name><name><surname>Borowek</surname><given-names>A</given-names></name><name><surname>Noeparast</surname><given-names>M</given-names></name><name><surname>Pavlakis</surname><given-names>E</given-names></name><name><surname>Neumann</surname><given-names>M</given-names></name><name><surname>Balourdas</surname><given-names>DI</given-names></name><name><surname>Kochhan</surname><given-names>K</given-names></name><name><surname>Merle</surname><given-names>N</given-names></name><name><surname>Bullwinkel</surname><given-names>I</given-names></name><name><surname>Wanzel</surname><given-names>M</given-names></name><name><surname>Elmshäuser</surname><given-names>S</given-names></name><name><surname>Teply-Szymanski</surname><given-names>J</given-names></name><name><surname>Nist</surname><given-names>A</given-names></name><name><surname>Procida</surname><given-names>T</given-names></name><name><surname>Bartkuhn</surname><given-names>M</given-names></name><name><surname>Humpert</surname><given-names>K</given-names></name><name><surname>Mernberger</surname><given-names>M</given-names></name><name><surname>Savai</surname><given-names>R</given-names></name><name><surname>Soussi</surname><given-names>T</given-names></name><name><surname>Joerger</surname><given-names>AC</given-names></name><name><surname>Stiewe</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations</article-title><source>Nature Genetics</source><volume>57</volume><fpage>140</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1038/s41588-024-02039-4</pub-id><pub-id pub-id-type="pmid">39774325</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gencel-Augusto</surname><given-names>J</given-names></name><name><surname>Lozano</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>p53 tetramerization: at the center of the dominant-negative effect of mutant p53</article-title><source>Genes &amp; Development</source><volume>34</volume><fpage>1128</fpage><lpage>1146</lpage><pub-id pub-id-type="doi">10.1101/gad.340976.120</pub-id><pub-id pub-id-type="pmid">32873579</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gener-Ricos</surname><given-names>G</given-names></name><name><surname>Bewersdorf</surname><given-names>JP</given-names></name><name><surname>Loghavi</surname><given-names>S</given-names></name><name><surname>Bataller</surname><given-names>A</given-names></name><name><surname>Goldberg</surname><given-names>AD</given-names></name><name><surname>Sasaki</surname><given-names>K</given-names></name><name><surname>Famulare</surname><given-names>C</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Issa</surname><given-names>GC</given-names></name><name><surname>Borthakur</surname><given-names>G</given-names></name><name><surname>Kadia</surname><given-names>TM</given-names></name><name><surname>Short</surname><given-names>NJ</given-names></name><name><surname>Senapati</surname><given-names>J</given-names></name><name><surname>Carter</surname><given-names>BZ</given-names></name><name><surname>Patel</surname><given-names>KP</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name><name><surname>Andreeff</surname><given-names>M</given-names></name><name><surname>Stein</surname><given-names>EM</given-names></name><name><surname>DiNardo</surname><given-names>CD</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title><italic>TP53</italic> Y220C mutations in patients with myeloid malignancies</article-title><source>Leukemia &amp; Lymphoma</source><volume>65</volume><fpage>1511</fpage><lpage>1515</lpage><pub-id pub-id-type="doi">10.1080/10428194.2024.2363440</pub-id><pub-id pub-id-type="pmid">38856690</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greten</surname><given-names>FR</given-names></name><name><surname>Grivennikov</surname><given-names>SI</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Inflammation and cancer: triggers, mechanisms, and consequences</article-title><source>Immunity</source><volume>51</volume><fpage>27</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2019.06.025</pub-id><pub-id pub-id-type="pmid">31315034</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guimond</surname><given-names>MJ</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Fujita</surname><given-names>J</given-names></name><name><surname>Terhorst</surname><given-names>C</given-names></name><name><surname>Croy</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Pregnancy-associated uterine granulated metrial gland cells in mutant and transgenic mice</article-title><source>American Journal of Reproductive Immunology</source><volume>35</volume><fpage>501</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0897.1996.tb00049.x</pub-id><pub-id pub-id-type="pmid">8792932</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hainaut</surname><given-names>P</given-names></name><name><surname>Pfeifer</surname><given-names>GP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Somatic TP53 mutations in the era of genome sequencing</article-title><source>Cold Spring Harbor Perspectives in Medicine</source><volume>6</volume><elocation-id>a026179</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a026179</pub-id><pub-id pub-id-type="pmid">27503997</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ham</surname><given-names>SW</given-names></name><name><surname>Jeon</surname><given-names>HY</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Kim</surname><given-names>EJ</given-names></name><name><surname>Kim</surname><given-names>JK</given-names></name><name><surname>Shin</surname><given-names>YJ</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Seo</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>MG</given-names></name><name><surname>Kim</surname><given-names>HM</given-names></name><name><surname>Nam</surname><given-names>DH</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>TP53 gain-of-function mutation promotes inflammation in glioblastoma</article-title><source>Cell Death and Differentiation</source><volume>26</volume><fpage>409</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1038/s41418-018-0126-3</pub-id><pub-id pub-id-type="pmid">29786075</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Hallmarks of cancer: new dimensions</article-title><source>Cancer Discovery</source><volume>12</volume><fpage>31</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-21-1059</pub-id><pub-id pub-id-type="pmid">35022204</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanel</surname><given-names>W</given-names></name><name><surname>Marchenko</surname><given-names>N</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>SX</given-names></name><name><surname>Weng</surname><given-names>W</given-names></name><name><surname>Moll</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis</article-title><source>Cell Death and Differentiation</source><volume>20</volume><fpage>898</fpage><lpage>909</lpage><pub-id pub-id-type="doi">10.1038/cdd.2013.17</pub-id><pub-id pub-id-type="pmid">23538418</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollstein</surname><given-names>M</given-names></name><name><surname>Sidransky</surname><given-names>D</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Harris</surname><given-names>CC</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>p53 mutations in human cancers</article-title><source>Science</source><volume>253</volume><fpage>49</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1126/science.1905840</pub-id><pub-id pub-id-type="pmid">1905840</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name><name><surname>Teresky</surname><given-names>AK</given-names></name><name><surname>Levine</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>p53 regulates maternal reproduction through LIF</article-title><source>Nature</source><volume>450</volume><fpage>721</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1038/nature05993</pub-id><pub-id pub-id-type="pmid">18046411</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The role of p53 gene family in reproduction</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>1</volume><elocation-id>a001073</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a001073</pub-id><pub-id pub-id-type="pmid">20457559</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humpton</surname><given-names>TJ</given-names></name><name><surname>Hock</surname><given-names>AK</given-names></name><name><surname>Maddocks</surname><given-names>ODK</given-names></name><name><surname>Vousden</surname><given-names>KH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>p53-mediated adaptation to serine starvation is retained by a common tumour-derived mutant</article-title><source>Cancer &amp; Metabolism</source><volume>6</volume><elocation-id>18</elocation-id><pub-id pub-id-type="doi">10.1186/s40170-018-0191-6</pub-id><pub-id pub-id-type="pmid">30524726</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwakuma</surname><given-names>T</given-names></name><name><surname>Parant</surname><given-names>JM</given-names></name><name><surname>Fasulo</surname><given-names>M</given-names></name><name><surname>Zwart</surname><given-names>E</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name><name><surname>de Vries</surname><given-names>A</given-names></name><name><surname>Lozano</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice</article-title><source>Oncogene</source><volume>23</volume><fpage>7644</fpage><lpage>7650</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1207793</pub-id><pub-id pub-id-type="pmid">15361844</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacks</surname><given-names>T</given-names></name><name><surname>Remington</surname><given-names>L</given-names></name><name><surname>Williams</surname><given-names>BO</given-names></name><name><surname>Schmitt</surname><given-names>EM</given-names></name><name><surname>Halachmi</surname><given-names>S</given-names></name><name><surname>Bronson</surname><given-names>RT</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Tumor spectrum analysis in p53-mutant mice</article-title><source>Current Biology</source><volume>4</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/s0960-9822(00)00002-6</pub-id><pub-id pub-id-type="pmid">7922305</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joerger</surname><given-names>AC</given-names></name><name><surname>Ang</surname><given-names>HC</given-names></name><name><surname>Fersht</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Structural basis for understanding oncogenic p53 mutations and designing rescue drugs</article-title><source>PNAS</source><volume>103</volume><fpage>15056</fpage><lpage>15061</lpage><pub-id pub-id-type="doi">10.1073/pnas.0607286103</pub-id><pub-id pub-id-type="pmid">17015838</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>SN</given-names></name><name><surname>Roe</surname><given-names>AE</given-names></name><name><surname>Donehower</surname><given-names>LA</given-names></name><name><surname>Bradley</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53</article-title><source>Nature</source><volume>378</volume><fpage>206</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1038/378206a0</pub-id><pub-id pub-id-type="pmid">7477327</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadosh</surname><given-names>E</given-names></name><name><surname>Snir-Alkalay</surname><given-names>I</given-names></name><name><surname>Venkatachalam</surname><given-names>A</given-names></name><name><surname>May</surname><given-names>S</given-names></name><name><surname>Lasry</surname><given-names>A</given-names></name><name><surname>Elyada</surname><given-names>E</given-names></name><name><surname>Zinger</surname><given-names>A</given-names></name><name><surname>Shaham</surname><given-names>M</given-names></name><name><surname>Vaalani</surname><given-names>G</given-names></name><name><surname>Mernberger</surname><given-names>M</given-names></name><name><surname>Stiewe</surname><given-names>T</given-names></name><name><surname>Pikarsky</surname><given-names>E</given-names></name><name><surname>Oren</surname><given-names>M</given-names></name><name><surname>Ben-Neriah</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic</article-title><source>Nature</source><volume>586</volume><fpage>133</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2541-0</pub-id><pub-id pub-id-type="pmid">32728212</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karthik</surname><given-names>KV</given-names></name><name><surname>Rajalingam</surname><given-names>A</given-names></name><name><surname>Shivashankar</surname><given-names>M</given-names></name><name><surname>Ganjiwale</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Recursive feature elimination-based biomarker identification for open neural tube defects</article-title><source>Current Genomics</source><volume>23</volume><fpage>195</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.2174/1389202923666220511162038</pub-id><pub-id pub-id-type="pmid">36777008</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kastan</surname><given-names>MB</given-names></name><name><surname>Zhan</surname><given-names>Q</given-names></name><name><surname>el-Deiry</surname><given-names>WS</given-names></name><name><surname>Carrier</surname><given-names>F</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name><name><surname>Walsh</surname><given-names>WV</given-names></name><name><surname>Plunkett</surname><given-names>BS</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Fornace</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia</article-title><source>Cell</source><volume>71</volume><fpage>587</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(92)90593-2</pub-id><pub-id pub-id-type="pmid">1423616</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>MC</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Mutant p53: it’s not all one and the same</article-title><source>Cell Death and Differentiation</source><volume>29</volume><fpage>983</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.1038/s41418-022-00989-y</pub-id><pub-id pub-id-type="pmid">35361963</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Deppert</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Interactions of mutant p53 with DNA: guilt by association</article-title><source>Oncogene</source><volume>26</volume><fpage>2185</fpage><lpage>2190</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210312</pub-id><pub-id pub-id-type="pmid">17401427</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MP</given-names></name><name><surname>Lozano</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mutant p53 partners in crime</article-title><source>Cell Death and Differentiation</source><volume>25</volume><fpage>161</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1038/cdd.2017.185</pub-id><pub-id pub-id-type="pmid">29099488</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotler</surname><given-names>E</given-names></name><name><surname>Shani</surname><given-names>O</given-names></name><name><surname>Goldfeld</surname><given-names>G</given-names></name><name><surname>Lotan-Pompan</surname><given-names>M</given-names></name><name><surname>Tarcic</surname><given-names>O</given-names></name><name><surname>Gershoni</surname><given-names>A</given-names></name><name><surname>Hopf</surname><given-names>TA</given-names></name><name><surname>Marks</surname><given-names>DS</given-names></name><name><surname>Oren</surname><given-names>M</given-names></name><name><surname>Segal</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A systematic p53 mutation library links differential functional impact to cancer mutation pattern and evolutionary conservation</article-title><source>Molecular Cell</source><volume>71</volume><fpage>178</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2018.06.012</pub-id><pub-id pub-id-type="pmid">29979965</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Pouyssegur</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Tumor cell metabolism: cancer’s Achilles’ heel</article-title><source>Cancer Cell</source><volume>13</volume><fpage>472</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2008.05.005</pub-id><pub-id pub-id-type="pmid">18538731</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lallemand</surname><given-names>Y</given-names></name><name><surname>Luria</surname><given-names>V</given-names></name><name><surname>Haffner-Krausz</surname><given-names>R</given-names></name><name><surname>Lonai</surname><given-names>P</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Maternally expressed PGK-Cre transgene as a tool for early and uniform activation of the Cre site-specific recombinase</article-title><source>Transgenic Research</source><volume>7</volume><fpage>105</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1023/a:1008868325009</pub-id><pub-id pub-id-type="pmid">9608738</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lian</surname><given-names>Q</given-names></name><name><surname>Dheen</surname><given-names>ST</given-names></name><name><surname>Liao</surname><given-names>D</given-names></name><name><surname>Tay</surname><given-names>SSW</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Enhanced inflammatory response in neural tubes of embryos derived from diabetic mice exposed to a teratogen</article-title><source>Journal of Neuroscience Research</source><volume>75</volume><fpage>554</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1002/jnr.20006</pub-id><pub-id pub-id-type="pmid">14743439</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>featureCounts: an efficient general purpose program for assigning sequence reads to genomic features</article-title><source>Bioinformatics</source><volume>30</volume><fpage>923</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btt656</pub-id><pub-id pub-id-type="pmid">24227677</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Pan</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>MDM4 was associated with poor prognosis and tumor-immune infiltration of cancers</article-title><source>European Journal of Medical Research</source><volume>29</volume><elocation-id>79</elocation-id><pub-id pub-id-type="doi">10.1186/s40001-024-01684-z</pub-id><pub-id pub-id-type="pmid">38281029</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowe</surname><given-names>SW</given-names></name><name><surname>Schmitt</surname><given-names>EM</given-names></name><name><surname>Smith</surname><given-names>SW</given-names></name><name><surname>Osborne</surname><given-names>BA</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>p53 is required for radiation-induced apoptosis in mouse thymocytes</article-title><source>Nature</source><volume>362</volume><fpage>847</fpage><lpage>849</lpage><pub-id pub-id-type="doi">10.1038/362847a0</pub-id><pub-id pub-id-type="pmid">8479522</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marine</surname><given-names>JC</given-names></name><name><surname>Francoz</surname><given-names>S</given-names></name><name><surname>Maetens</surname><given-names>M</given-names></name><name><surname>Wahl</surname><given-names>G</given-names></name><name><surname>Toledo</surname><given-names>F</given-names></name><name><surname>Lozano</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4</article-title><source>Cell Death and Differentiation</source><volume>13</volume><fpage>927</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4401912</pub-id><pub-id pub-id-type="pmid">16543935</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCann</surname><given-names>JJ</given-names></name><name><surname>Vasilevskaya</surname><given-names>IA</given-names></name><name><surname>McNair</surname><given-names>C</given-names></name><name><surname>Gallagher</surname><given-names>P</given-names></name><name><surname>Neupane</surname><given-names>NP</given-names></name><name><surname>de Leeuw</surname><given-names>R</given-names></name><name><surname>Shafi</surname><given-names>AA</given-names></name><name><surname>Dylgjeri</surname><given-names>E</given-names></name><name><surname>Mandigo</surname><given-names>AC</given-names></name><name><surname>Schiewer</surname><given-names>MJ</given-names></name><name><surname>Knudsen</surname><given-names>KE</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Mutant p53 elicits context-dependent pro-tumorigenic phenotypes</article-title><source>Oncogene</source><volume>41</volume><fpage>444</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1038/s41388-021-01903-5</pub-id><pub-id pub-id-type="pmid">34773073</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNairn</surname><given-names>AJ</given-names></name><name><surname>Chuang</surname><given-names>CH</given-names></name><name><surname>Bloom</surname><given-names>JC</given-names></name><name><surname>Wallace</surname><given-names>MD</given-names></name><name><surname>Schimenti</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Female-biased embryonic death from inflammation induced by genomic instability</article-title><source>Nature</source><volume>567</volume><fpage>105</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-0936-6</pub-id><pub-id pub-id-type="pmid">30787433</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Migliorini</surname><given-names>D</given-names></name><name><surname>Lazzerini Denchi</surname><given-names>E</given-names></name><name><surname>Danovi</surname><given-names>D</given-names></name><name><surname>Jochemsen</surname><given-names>A</given-names></name><name><surname>Capillo</surname><given-names>M</given-names></name><name><surname>Gobbi</surname><given-names>A</given-names></name><name><surname>Helin</surname><given-names>K</given-names></name><name><surname>Pelicci</surname><given-names>PG</given-names></name><name><surname>Marine</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development</article-title><source>Molecular and Cellular Biology</source><volume>22</volume><fpage>5527</fpage><lpage>5538</lpage><pub-id pub-id-type="doi">10.1128/MCB.22.15.5527-5538.2002</pub-id><pub-id pub-id-type="pmid">12101245</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montes de Oca Luna</surname><given-names>R</given-names></name><name><surname>Wagner</surname><given-names>DS</given-names></name><name><surname>Lozano</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53</article-title><source>Nature</source><volume>378</volume><fpage>203</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1038/378203a0</pub-id><pub-id pub-id-type="pmid">7477326</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morselli</surname><given-names>E</given-names></name><name><surname>Tasdemir</surname><given-names>E</given-names></name><name><surname>Maiuri</surname><given-names>MC</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Kepp</surname><given-names>O</given-names></name><name><surname>Criollo</surname><given-names>A</given-names></name><name><surname>Vicencio</surname><given-names>JM</given-names></name><name><surname>Soussi</surname><given-names>T</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Mutant p53 protein localized in the cytoplasm inhibits autophagy</article-title><source>Cell Cycle</source><volume>7</volume><fpage>3056</fpage><lpage>3061</lpage><pub-id pub-id-type="doi">10.4161/cc.7.19.6751</pub-id><pub-id pub-id-type="pmid">18818522</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pal</surname><given-names>A</given-names></name><name><surname>Gonzalez-Malerva</surname><given-names>L</given-names></name><name><surname>Eaton</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Grief</surname><given-names>D</given-names></name><name><surname>Sakala</surname><given-names>L</given-names></name><name><surname>Nwekwo</surname><given-names>L</given-names></name><name><surname>Zeng</surname><given-names>J</given-names></name><name><surname>Christensen</surname><given-names>G</given-names></name><name><surname>Gupta</surname><given-names>C</given-names></name><name><surname>Streitwieser</surname><given-names>E</given-names></name><name><surname>Singharoy</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>JG</given-names></name><name><surname>LaBaer</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Multidimensional quantitative phenotypic and molecular analysis reveals neomorphic behaviors of p53 missense mutants</article-title><source>NPJ Breast Cancer</source><volume>9</volume><elocation-id>78</elocation-id><pub-id pub-id-type="doi">10.1038/s41523-023-00582-7</pub-id><pub-id pub-id-type="pmid">37773066</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parant</surname><given-names>J</given-names></name><name><surname>Chavez-Reyes</surname><given-names>A</given-names></name><name><surname>Little</surname><given-names>NA</given-names></name><name><surname>Yan</surname><given-names>W</given-names></name><name><surname>Reinke</surname><given-names>V</given-names></name><name><surname>Jochemsen</surname><given-names>AG</given-names></name><name><surname>Lozano</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53</article-title><source>Nature Genetics</source><volume>29</volume><fpage>92</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1038/ng714</pub-id><pub-id pub-id-type="pmid">11528400</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfister</surname><given-names>NT</given-names></name><name><surname>Prives</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Transcriptional regulation by wild-type and cancer-related mutant forms of p53</article-title><source>Cold Spring Harbor Perspectives in Medicine</source><volume>7</volume><elocation-id>a026054</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a026054</pub-id><pub-id pub-id-type="pmid">27836911</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rakotopare</surname><given-names>J</given-names></name><name><surname>Lejour</surname><given-names>V</given-names></name><name><surname>Duval</surname><given-names>C</given-names></name><name><surname>Eldawra</surname><given-names>E</given-names></name><name><surname>Escoffier</surname><given-names>H</given-names></name><name><surname>Toledo</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>A systematic approach identifies p53-DREAM pathway target genes associated with blood or brain abnormalities</article-title><source>Disease Models &amp; Mechanisms</source><volume>16</volume><elocation-id>dmm050376</elocation-id><pub-id pub-id-type="doi">10.1242/dmm.050376</pub-id><pub-id pub-id-type="pmid">37661832</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rakotopare</surname><given-names>J</given-names></name><name><surname>Toledo</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>p53 in the molecular circuitry of bone marrow failure syndromes</article-title><source>International Journal of Molecular Sciences</source><volume>24</volume><elocation-id>14940</elocation-id><pub-id pub-id-type="doi">10.3390/ijms241914940</pub-id><pub-id pub-id-type="pmid">37834388</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rambold</surname><given-names>AS</given-names></name><name><surname>Lippincott-Schwartz</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Mechanisms of mitochondria and autophagy crosstalk</article-title><source>Cell Cycle</source><volume>10</volume><fpage>4032</fpage><lpage>4038</lpage><pub-id pub-id-type="doi">10.4161/cc.10.23.18384</pub-id><pub-id pub-id-type="pmid">22101267</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regeling</surname><given-names>A</given-names></name><name><surname>Armata</surname><given-names>HL</given-names></name><name><surname>Gallant</surname><given-names>J</given-names></name><name><surname>Jones</surname><given-names>SN</given-names></name><name><surname>Sluss</surname><given-names>HK</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Mice defective in p53 nuclear localization signal 1 exhibit exencephaly</article-title><source>Transgenic Research</source><volume>20</volume><fpage>899</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.1007/s11248-010-9468-4</pub-id><pub-id pub-id-type="pmid">21127973</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rockwell</surname><given-names>NC</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Warrington</surname><given-names>NM</given-names></name><name><surname>Staller</surname><given-names>MV</given-names></name><name><surname>Griffith</surname><given-names>M</given-names></name><name><surname>Griffith</surname><given-names>OL</given-names></name><name><surname>Gurnett</surname><given-names>CA</given-names></name><name><surname>Cohen</surname><given-names>BA</given-names></name><name><surname>Baldridge</surname><given-names>D</given-names></name><name><surname>Rubin</surname><given-names>JB</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Sex- and mutation-specific p53 gain-of-function activity in gliomagenesis</article-title><source>Cancer Research Communications</source><volume>1</volume><fpage>148</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1158/2767-9764.crc-21-0026</pub-id><pub-id pub-id-type="pmid">34957471</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodier</surname><given-names>F</given-names></name><name><surname>Coppé</surname><given-names>J-P</given-names></name><name><surname>Patil</surname><given-names>CK</given-names></name><name><surname>Hoeijmakers</surname><given-names>WAM</given-names></name><name><surname>Muñoz</surname><given-names>DP</given-names></name><name><surname>Raza</surname><given-names>SR</given-names></name><name><surname>Freund</surname><given-names>A</given-names></name><name><surname>Campeau</surname><given-names>E</given-names></name><name><surname>Davalos</surname><given-names>AR</given-names></name><name><surname>Campisi</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion</article-title><source>Nature Cell Biology</source><volume>11</volume><fpage>973</fpage><lpage>979</lpage><pub-id pub-id-type="doi">10.1038/ncb1909</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sah</surname><given-names>VP</given-names></name><name><surname>Attardi</surname><given-names>LD</given-names></name><name><surname>Mulligan</surname><given-names>GJ</given-names></name><name><surname>Williams</surname><given-names>BO</given-names></name><name><surname>Bronson</surname><given-names>RT</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>A subset of p53-deficient embryos exhibit exencephaly</article-title><source>Nature Genetics</source><volume>10</volume><fpage>175</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1038/ng0695-175</pub-id><pub-id pub-id-type="pmid">7663512</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirole</surname><given-names>NH</given-names></name><name><surname>Pal</surname><given-names>D</given-names></name><name><surname>Kastenhuber</surname><given-names>ER</given-names></name><name><surname>Senturk</surname><given-names>S</given-names></name><name><surname>Boroda</surname><given-names>J</given-names></name><name><surname>Pisterzi</surname><given-names>P</given-names></name><name><surname>Miller</surname><given-names>M</given-names></name><name><surname>Munoz</surname><given-names>G</given-names></name><name><surname>Anderluh</surname><given-names>M</given-names></name><name><surname>Ladanyi</surname><given-names>M</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name><name><surname>Sordella</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title><italic>TP53</italic> exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions</article-title><source>eLife</source><volume>5</volume><elocation-id>e17929</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.17929</pub-id><pub-id pub-id-type="pmid">27759562</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simeonova</surname><given-names>I</given-names></name><name><surname>Lejour</surname><given-names>V</given-names></name><name><surname>Bardot</surname><given-names>B</given-names></name><name><surname>Bouarich Bourimi</surname><given-names>R</given-names></name><name><surname>Morin</surname><given-names>A</given-names></name><name><surname>Fang</surname><given-names>M</given-names></name><name><surname>Charbonnier</surname><given-names>L</given-names></name><name><surname>Toledo</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fuzzy tandem repeats containing p53 response elements may define species-specific p53 target genes</article-title><source>PLOS Genetics</source><volume>8</volume><elocation-id>e1002731</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1002731</pub-id><pub-id pub-id-type="pmid">22761580</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simeonova</surname><given-names>I</given-names></name><name><surname>Jaber</surname><given-names>S</given-names></name><name><surname>Draskovic</surname><given-names>I</given-names></name><name><surname>Bardot</surname><given-names>B</given-names></name><name><surname>Fang</surname><given-names>M</given-names></name><name><surname>Bouarich-Bourimi</surname><given-names>R</given-names></name><name><surname>Lejour</surname><given-names>V</given-names></name><name><surname>Charbonnier</surname><given-names>L</given-names></name><name><surname>Soudais</surname><given-names>C</given-names></name><name><surname>Bourdon</surname><given-names>JC</given-names></name><name><surname>Huerre</surname><given-names>M</given-names></name><name><surname>Londono-Vallejo</surname><given-names>A</given-names></name><name><surname>Toledo</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mutant mice lacking the p53 C-terminal domain model telomere syndromes</article-title><source>Cell Reports</source><volume>3</volume><fpage>2046</fpage><lpage>2058</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2013.05.028</pub-id><pub-id pub-id-type="pmid">23770245</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sionov</surname><given-names>RV</given-names></name><name><surname>Vlahopoulos</surname><given-names>SA</given-names></name><name><surname>Granot</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Regulation of bim in health and disease</article-title><source>Oncotarget</source><volume>6</volume><fpage>23058</fpage><lpage>23134</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.5492</pub-id><pub-id pub-id-type="pmid">26405162</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solier</surname><given-names>S</given-names></name><name><surname>Müller</surname><given-names>S</given-names></name><name><surname>Cañeque</surname><given-names>T</given-names></name><name><surname>Versini</surname><given-names>A</given-names></name><name><surname>Mansart</surname><given-names>A</given-names></name><name><surname>Sindikubwabo</surname><given-names>F</given-names></name><name><surname>Baron</surname><given-names>L</given-names></name><name><surname>Emam</surname><given-names>L</given-names></name><name><surname>Gestraud</surname><given-names>P</given-names></name><name><surname>Pantoș</surname><given-names>GD</given-names></name><name><surname>Gandon</surname><given-names>V</given-names></name><name><surname>Gaillet</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>TD</given-names></name><name><surname>Dingli</surname><given-names>F</given-names></name><name><surname>Loew</surname><given-names>D</given-names></name><name><surname>Baulande</surname><given-names>S</given-names></name><name><surname>Durand</surname><given-names>S</given-names></name><name><surname>Sencio</surname><given-names>V</given-names></name><name><surname>Robil</surname><given-names>C</given-names></name><name><surname>Trottein</surname><given-names>F</given-names></name><name><surname>Péricat</surname><given-names>D</given-names></name><name><surname>Näser</surname><given-names>E</given-names></name><name><surname>Cougoule</surname><given-names>C</given-names></name><name><surname>Meunier</surname><given-names>E</given-names></name><name><surname>Bègue</surname><given-names>AL</given-names></name><name><surname>Salmon</surname><given-names>H</given-names></name><name><surname>Manel</surname><given-names>N</given-names></name><name><surname>Puisieux</surname><given-names>A</given-names></name><name><surname>Watson</surname><given-names>S</given-names></name><name><surname>Dawson</surname><given-names>MA</given-names></name><name><surname>Servant</surname><given-names>N</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Annane</surname><given-names>D</given-names></name><name><surname>Rodriguez</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>A druggable copper-signalling pathway that drives inflammation</article-title><source>Nature</source><volume>617</volume><fpage>386</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06017-4</pub-id><pub-id pub-id-type="pmid">37100912</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>Y</given-names></name><name><surname>Aloni-Grinstein</surname><given-names>R</given-names></name><name><surname>Rotter</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mutant p53 oncogenicity: dominant-negative or gain-of-function?</article-title><source>Carcinogenesis</source><volume>41</volume><fpage>1635</fpage><lpage>1647</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgaa117</pub-id><pub-id pub-id-type="pmid">33159515</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Gillette</surname><given-names>MA</given-names></name><name><surname>Paulovich</surname><given-names>A</given-names></name><name><surname>Pomeroy</surname><given-names>SL</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>PNAS</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmid">16199517</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tateossian</surname><given-names>H</given-names></name><name><surname>Morse</surname><given-names>S</given-names></name><name><surname>Simon</surname><given-names>MM</given-names></name><name><surname>Dean</surname><given-names>CH</given-names></name><name><surname>Brown</surname><given-names>SDM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Interactions between the otitis media gene, Fbxo11, and p53 in the mouse embryonic lung</article-title><source>Disease Models &amp; Mechanisms</source><volume>8</volume><fpage>1531</fpage><lpage>1542</lpage><pub-id pub-id-type="doi">10.1242/dmm.022426</pub-id><pub-id pub-id-type="pmid">26471094</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>AW</given-names></name><name><surname>Ng</surname><given-names>TF</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Negative regulators that mediate ocular immune privilege</article-title><source>Journal of Leukocyte Biology</source><volume>103</volume><fpage>1179</fpage><lpage>1187</lpage><pub-id pub-id-type="doi">10.1002/JLB.3MIR0817-337R</pub-id><pub-id pub-id-type="pmid">29431864</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toledo</surname><given-names>F</given-names></name><name><surname>Krummel</surname><given-names>KA</given-names></name><name><surname>Lee</surname><given-names>CJ</given-names></name><name><surname>Liu</surname><given-names>CW</given-names></name><name><surname>Rodewald</surname><given-names>LW</given-names></name><name><surname>Tang</surname><given-names>M</given-names></name><name><surname>Wahl</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network</article-title><source>Cancer Cell</source><volume>9</volume><fpage>273</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2006.03.014</pub-id><pub-id pub-id-type="pmid">16616333</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tseng</surname><given-names>TH</given-names></name><name><surname>Wang</surname><given-names>CJ</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Shao</surname><given-names>YC</given-names></name><name><surname>Shen</surname><given-names>CH</given-names></name><name><surname>Lee</surname><given-names>KC</given-names></name><name><surname>Tung</surname><given-names>SY</given-names></name><name><surname>Kuo</surname><given-names>HC</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Suppression of the proliferation of huh7 hepatoma cells involving the downregulation of mutant p53 protein and inactivation of the stat 3 pathway with ailanthoidol</article-title><source>International Journal of Molecular Sciences</source><volume>23</volume><elocation-id>5102</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23095102</pub-id><pub-id pub-id-type="pmid">35563493</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varner</surname><given-names>MW</given-names></name><name><surname>Costantine</surname><given-names>MM</given-names></name><name><surname>Jablonski</surname><given-names>KA</given-names></name><name><surname>Rouse</surname><given-names>DJ</given-names></name><name><surname>Mercer</surname><given-names>BM</given-names></name><name><surname>Leveno</surname><given-names>KJ</given-names></name><name><surname>Reddy</surname><given-names>UM</given-names></name><name><surname>Buhimschi</surname><given-names>C</given-names></name><name><surname>Wapner</surname><given-names>RJ</given-names></name><name><surname>Sorokin</surname><given-names>Y</given-names></name><name><surname>Thorp</surname><given-names>JM</given-names></name><name><surname>Ramin</surname><given-names>SM</given-names></name><name><surname>Malone</surname><given-names>FD</given-names></name><name><surname>Carpenter</surname><given-names>M</given-names></name><name><surname>O’sullivan</surname><given-names>MJ</given-names></name><name><surname>Peaceman</surname><given-names>AM</given-names></name><name><surname>Dudley</surname><given-names>DJ</given-names></name><name><surname>Caritis</surname><given-names>SN</given-names></name><collab>Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Sex-specific genetic susceptibility to adverse neurodevelopmental outcome in offspring of pregnancies at risk of early preterm delivery</article-title><source>American Journal of Perinatology</source><volume>37</volume><fpage>281</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1055/s-0039-1678535</pub-id><pub-id pub-id-type="pmid">30731481</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vassilev</surname><given-names>LT</given-names></name><name><surname>Vu</surname><given-names>BT</given-names></name><name><surname>Graves</surname><given-names>B</given-names></name><name><surname>Carvajal</surname><given-names>D</given-names></name><name><surname>Podlaski</surname><given-names>F</given-names></name><name><surname>Filipovic</surname><given-names>Z</given-names></name><name><surname>Kong</surname><given-names>N</given-names></name><name><surname>Kammlott</surname><given-names>U</given-names></name><name><surname>Lukacs</surname><given-names>C</given-names></name><name><surname>Klein</surname><given-names>C</given-names></name><name><surname>Fotouhi</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>In vivo activation of the p53 pathway by small-molecule antagonists of MDM2</article-title><source>Science</source><volume>303</volume><fpage>844</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1126/science.1092472</pub-id><pub-id pub-id-type="pmid">14704432</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ventura</surname><given-names>A</given-names></name><name><surname>Kirsch</surname><given-names>DG</given-names></name><name><surname>McLaughlin</surname><given-names>ME</given-names></name><name><surname>Tuveson</surname><given-names>DA</given-names></name><name><surname>Grimm</surname><given-names>J</given-names></name><name><surname>Lintault</surname><given-names>L</given-names></name><name><surname>Newman</surname><given-names>J</given-names></name><name><surname>Reczek</surname><given-names>EE</given-names></name><name><surname>Weissleder</surname><given-names>R</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Restoration of p53 function leads to tumour regression in vivo</article-title><source>Nature</source><volume>445</volume><fpage>661</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1038/nature05541</pub-id><pub-id pub-id-type="pmid">17251932</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vikhanskaya</surname><given-names>F</given-names></name><name><surname>Lee</surname><given-names>MK</given-names></name><name><surname>Mazzoletti</surname><given-names>M</given-names></name><name><surname>Broggini</surname><given-names>M</given-names></name><name><surname>Sabapathy</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53</article-title><source>Nucleic Acids Research</source><volume>35</volume><fpage>2093</fpage><lpage>2104</lpage><pub-id pub-id-type="doi">10.1093/nar/gkm099</pub-id><pub-id pub-id-type="pmid">17344317</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voskarides</surname><given-names>K</given-names></name><name><surname>Giannopoulou</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The role of tp53 in adaptation and evolution</article-title><source>Cells</source><volume>12</volume><elocation-id>512</elocation-id><pub-id pub-id-type="doi">10.3390/cells12030512</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vousden</surname><given-names>KH</given-names></name><name><surname>Lane</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>p53 in health and disease</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>8</volume><fpage>275</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1038/nrm2147</pub-id><pub-id pub-id-type="pmid">17380161</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Burigotto</surname><given-names>M</given-names></name><name><surname>Ghetti</surname><given-names>S</given-names></name><name><surname>Vaillant</surname><given-names>F</given-names></name><name><surname>Tan</surname><given-names>T</given-names></name><name><surname>Capaldo</surname><given-names>BD</given-names></name><name><surname>Palmieri</surname><given-names>M</given-names></name><name><surname>Hirokawa</surname><given-names>Y</given-names></name><name><surname>Tai</surname><given-names>L</given-names></name><name><surname>Simpson</surname><given-names>DS</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>AS</given-names></name><name><surname>Lieschke</surname><given-names>E</given-names></name><name><surname>Diepstraten</surname><given-names>ST</given-names></name><name><surname>Kaloni</surname><given-names>D</given-names></name><name><surname>Riffkin</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>DCS</given-names></name><name><surname>Li Wai Suen</surname><given-names>CSN</given-names></name><name><surname>Garnham</surname><given-names>AL</given-names></name><name><surname>Gibbs</surname><given-names>P</given-names></name><name><surname>Visvader</surname><given-names>JE</given-names></name><name><surname>Sieber</surname><given-names>OM</given-names></name><name><surname>Herold</surname><given-names>MJ</given-names></name><name><surname>Fava</surname><given-names>LL</given-names></name><name><surname>Kelly</surname><given-names>GL</given-names></name><name><surname>Strasser</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Loss-of-function but not gain-of-function properties of mutant tp53 are critical for the proliferation, survival, and metastasis of a broad range of cancer cells</article-title><source>Cancer Discovery</source><volume>14</volume><fpage>362</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-23-0402</pub-id><pub-id pub-id-type="pmid">37877779</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>S</given-names></name><name><surname>Chachad</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Gencel-Augusto</surname><given-names>J</given-names></name><name><surname>Sirito</surname><given-names>M</given-names></name><name><surname>Pant</surname><given-names>V</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Chau</surname><given-names>G</given-names></name><name><surname>Qi</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>X</given-names></name><name><surname>Whitley</surname><given-names>EM</given-names></name><name><surname>El-Naggar</surname><given-names>AK</given-names></name><name><surname>Lozano</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Differential gain-of-function activity of three p53 hotspot mutants in vivo</article-title><source>Cancer Research</source><volume>82</volume><fpage>1926</fpage><lpage>1936</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-21-3376</pub-id><pub-id pub-id-type="pmid">35320355</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Qian</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Fang</surname><given-names>JY</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Heterogeneity of Li-Fraumeni Syndrome links to unequal gain-of-function effects of p53 mutations</article-title><source>Scientific Reports</source><volume>4</volume><elocation-id>4223</elocation-id><pub-id pub-id-type="doi">10.1038/srep04223</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>J</given-names></name><name><surname>Tong</surname><given-names>Y</given-names></name><name><surname>Lv</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Kuang</surname><given-names>L</given-names></name><name><surname>Su</surname><given-names>K</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Rare mutations in the autophagy-regulating gene AMBRA1 contribute to human neural tube defects</article-title><source>Human Mutation</source><volume>41</volume><fpage>1383</fpage><lpage>1393</lpage><pub-id pub-id-type="doi">10.1002/humu.24028</pub-id><pub-id pub-id-type="pmid">32333458</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Role of decidual natural killer cells in human pregnancy and related pregnancy complications</article-title><source>Frontiers in Immunology</source><volume>12</volume><elocation-id>728291</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.728291</pub-id><pub-id pub-id-type="pmid">34512661</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>YH</given-names></name><name><surname>Dong</surname><given-names>XT</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>SX</given-names></name><name><surname>Xia</surname><given-names>MZ</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>DX</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Folic acid protects against lipopolysaccharide-induced preterm delivery and intrauterine growth restriction through its anti-inflammatory effect in mice</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e82713</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0082713</pub-id><pub-id pub-id-type="pmid">24324824</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Qu</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>p53 mutant p53 <sup>N236S</sup> induces neural tube defects in female embryos</article-title><source>International Journal of Biological Sciences</source><volume>15</volume><fpage>2006</fpage><lpage>2015</lpage><pub-id pub-id-type="doi">10.7150/ijbs.31451</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Gleber-Netto</surname><given-names>FO</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>McGrail</surname><given-names>DJ</given-names></name><name><surname>Gomez</surname><given-names>JA</given-names></name><name><surname>Ju</surname><given-names>W</given-names></name><name><surname>Gadhikar</surname><given-names>MA</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Pathak</surname><given-names>S</given-names></name><name><surname>Raso</surname><given-names>MG</given-names></name><name><surname>Burks</surname><given-names>JK</given-names></name><name><surname>Lin</surname><given-names>SY</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Multani</surname><given-names>AS</given-names></name><name><surname>Pickering</surname><given-names>CR</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Myers</surname><given-names>JN</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response</article-title><source>Nature Communications</source><volume>15</volume><elocation-id>180</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-023-44239-2</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Mallio</surname><given-names>CA</given-names></name><name><surname>Rossi</surname><given-names>G</given-names></name><name><surname>Jalal</surname><given-names>AH</given-names></name><name><surname>Filipovic</surname><given-names>N</given-names></name><name><surname>Tian</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Triptolide promotes degradation of the unfolded gain-of-function Tp53<sup>R175H/Y220C</sup> mutant protein by initiating heat shock protein 70 transcription in non-small cell lung cancer</article-title><source>Translational Lung Cancer Research</source><volume>11</volume><fpage>802</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.21037/tlcr-22-312</pub-id><pub-id pub-id-type="pmid">35693277</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.102434.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lal</surname><given-names>Ashish</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>National Cancer Institute</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Exceptional</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Fundamental</kwd></kwd-group></front-stub><body><p>This work is of <bold>fundamental</bold> significance and has an <bold>exceptional</bold> level of evidence for the role of a mutant p53 in regulation of tumorigenesis using an in vivo mouse model. The study is well-conducted and will be of interest to a broad audience including those interested in p53, transcription factors and cancer biology.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.102434.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This manuscript by Toledo and colleagues describes the generation and characterization of Y220C mice (Y217C in the mouse allele). The authors make notable findings: Y217C mice that have been backcrossed to C57Bl/6 for five generations show decreased female pup births due to exencephaly, a known defect in p53 -/- mice, and they show a correlation with decreased Xist expression, as well as increased female neonatal death. They also noted similar tumor formation in Y217C/+ and p53 +/- mice, suggesting that Y217C may not function as a dominant negative. Notably, the authors find that homozygous Y217C mice die faster than p53 -/- mice, and that the lymphomas in the Y217C mice were more aggressive and invasive. The authors then perform RNA seq on thymi of Y217C homozygotes compared to p53 -/-, and they suggest that these differentially expressed genes may explain the increased tumorigenesis in Y217C mice.</p><p>Strengths:</p><p>Overall, the study is well controlled and quite well done and will be of interest to a broad audience, particularly given the high frequency of the Y220C mutation in cancer (1% of all cancers, 4% of ovarian cancer).</p><p>Weaknesses:</p><p>None noted</p><p>Comments on revisions:</p><p>The authors have done a superb job on this very interesting work.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.102434.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>Jaber et al. describe the generation and characterization of a knock-in mouse strain expressing the p53 Y217C hot-spot mutation. While the homozygous mutant cells and mice reflect the typical loss-of-p53 functions, as expected, the Y217C mutation also appears to display gain-of function (GOF) properties, exemplified by elevated metastasis in the homozygous context (as noted with several hot-spot mutations). Interestingly, this mutation does not appear to exhibit any dominant-negative effects associated with most hot-spot p53 mutations, as determined by absence of differences in overall survival and tumor predisposition of the heterozygous mice, as well as target gene activation upon nutlin treatment.</p><p>In addition, the authors noted a severe reduction in the female 217/217 homozygous progeny, significantly more than that observed with the p53 null mice, due to exencephaly, leading them to conclude that the Y217C mutation also has additional, non-cancer related GOFs. Thought this property has been well described and attributed to p53 functional impairment, the authors conclude that the Y217C has additional properties in accelerating the phenotype.</p><p>Transcriptomic analyses of thymi found additional gene signature differences between p53 null and the Y217C strains, indicative of novel target gene activation, associated with inflammation.</p><p>Strengths:</p><p>Overall, the characterisation of the mice highlights the expected typical outcomes associated with most hot-spot p53 mutations published earlier. The quality of the work presented is well done and good, and the conclusions and reasonably well justified.</p><p>Comments on revisions:</p><p>Revised version has addressed most of our queries and is acceptable.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.102434.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jaber</surname><given-names>Sara</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Curie</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Eldawra</surname><given-names>Eliana</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Curie</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Rakotopare</surname><given-names>Jeanne</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Curie</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Simeonova</surname><given-names>Iva</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Curie</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Lejour</surname><given-names>Vincent</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Curie</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Gabriel</surname><given-names>Marc</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Curie</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Cañeque</surname><given-names>Tatiana</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Curie</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Volochtchouk</surname><given-names>Vitalina</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Curie</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Licaj</surname><given-names>Monika</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Curie</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Fajac</surname><given-names>Anne</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Curie</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Rodriguez</surname><given-names>Raphaël</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Curie</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Morillon</surname><given-names>Antonin</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Curie</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Bardot</surname><given-names>Boris</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Curie</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Toledo</surname><given-names>Franck</given-names></name><role specific-use="author">Author</role><aff><institution>Sorbonne University, Institut Curie</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews</p><p>Reviewer #2 suggested the addition of new data to address the following points:</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2:</bold></p><p>(1) Oncogenic GOF - the main data shown for GOF are the survival curve and enhanced metastasis. Often, GOF is exemplified at the cellular level as enhanced migration and invasion, which are standard assays to support the GOF. As such, the authors should perform these assays using either tumor cells derived from the mice or transformed fibroblasts from these mice. This will provide important and confirmatory evidence for GOF for Y217C.</p></disp-quote><p>We thank the referee for this comment. Our previous data indicated accelerated tumor progression and increased metastasis in <italic>Trp53</italic><sup>Y217C/Y217C</sup> mice, which provided in vivo evidence of an oncogenic gain of function (GOF) for the p53<sup>Y217C</sup> mutant. However, we agree that it was important to provide additional evidence of GOF at the cellular level.</p><p>Many cellular assays were previously used to evaluate the GOF of p53 mutants, including those listed by the referee. Importantly, Zhao et al. recently showed that a common property of several p53 mutants proposed to have oncogenic GOF is their capacity to promote chromosomal instability (Zhao et al. (2024) Nat. Commun. 15, 180). For the revision of our manuscript, we compared the frequencies of chromosomal alterations occurring spontaneously in WT, <italic>Trp53</italic><sup>Y217C/Y217C</sup> and <italic>Trp53-/-</italic> mouse embryonic fibroblasts (MEFs). Chromosome breaks, radial chromosomes and DMs were more frequent in <italic>Trp53</italic><sup>Y217C/Y217C</sup> MEFs than in WT or <italic>Trp53-/-</italic> MEFs, providing clear evidence of a GOF promoting chromosomal instability. This new result is presented in Figure 2G and mentioned in the revised abstract.</p><p>Furthermore, as pointed out by referee #1 in a confidential comment, increased NF-kB signaling provides evidence of p53 GOF. Accordingly, Zhao et al. proposed that the capacity of p53<sup>G245D</sup> and p53<sup>R273H</sup> to promote chromosomal instability ultimately led to activation of a noncanonical NF-kB signaling that would promote tumor cell invasion and metastasis. Consistent with their work, we now report that the GSEA of <italic>Trp53</italic><sup>Y217C/Y217C</sup> and <italic>Trp53-/-</italic> thymocytes revealed an upregulation of non-canonical NF-kB signaling in <italic>Trp53</italic><sup>Y217C/Y217C</sup> thymic cells (a new result presented in Figure 5F and Supplementary Figure S13). These new data lead us to mention in the revised discussion that “similar mechanisms might underlie the oncogenic properties of the p53<sup>Y217C</sup>, p53<sup>G245D</sup> and p53<sup>R273H</sup> mutants”.</p><disp-quote content-type="editor-comment"><p>(2) Novel target gene activation - while a set of novel targets appears to be increased in the Y217C cells compared to the p53 null cells, it is unclear how they are induced. The authors should examine if mutant p53 can bind to their promoters through CHIP assays, and, if these targets are specific to Y217C and not the other hot-spot mutations. This will strengthen the validity of the Y217C's ability to promote GOF.</p></disp-quote><p>We respectfully disagree with the referee when he/she considers that the validity of p53<sup>Y217C</sup>’s ability to promote a GOF would be strengthened by showing that p53<sup>Y217C</sup> binds to the promoters of genes upregulated in <italic>Trp53</italic><sup>Y217C/Y217C</sup> cells. In fact, Pal <italic>et al.</italic> recently performed the experiment proposed by the referee, by integrating RNAseq and ChIPseq data from MCF10A cells expressing p53<sup>Y220C</sup>, the human equivalent of p53<sup>Y217C</sup>, and found that 95% of the genes upregulated upon p53<sup>Y220C</sup> expression were upregulated indirectly, without p53<sup>Y220C</sup> binding to their promoters (Pal et al. (2023) NPJ Breast Cancer 9, 78). Consistent with our data, Pal et al. notably found that the expression of p53<sup>Y220C</sup> increased cell migration and invasion, which correlated with an increased expression of S100A8 and S100A9. They found that the promoters of S100A8 and S100A9 were however not bound by p53<sup>Y220C</sup>, indicating an indirect mechanism for their upregulated expression. Furthermore, the study by Zhao et al. mentioned above also suggested an indirect mechanism of GOF, because the upregulation of inflammation-related genes by a mutant p53 protein was proposed to result from signaling cascades triggered by chromosomal instability. Our data appear consistent with both studies, because p53<sup>Y217C</sup> was undetectable or barely detectable in the chromatin fraction of <italic>Trp53</italic><sup>Y217C/Y217C</sup> cells, and because <italic>Trp53</italic><sup>Y217C/Y217C</sup> cells exhibited increased chromosome instability and increased NFκB signaling compared to <italic>Trp53-/-</italic> cells, which may suggest indirect mechanisms for p53<sup>Y217C</sup> GOF.</p><p>Nevertheless, we agree with the referee that it was important to provide stronger evidence of p53<sup>Y217C</sup> GOF in the revised manuscript. In that regard, we were intrigued by the perinatal death of most <italic>Trp53</italic><sup>Y217C/Y217C</sup> females, which provided evidence of unexpected teratogenic effects of the mutant. We had proposed that these female-specific teratogenic effects likely resulted from pro-inflammatory GOF of p53<sup>Y217C</sup>. This hypothesis relied on the RNAseq pro-inflammatory signature in <italic>Trp53</italic><sup>Y217C/Y217C</sup> thymic cells, and on the fact that the glycoprotein CD44, known to drive inflammation, had been identified as a key gene in open neural tube defects. However, we had not tested this hypothesis experimentally. In the revised version of the manuscript, we tested this hypothesis. We mated <italic>Trp53</italic><sup>+/Y217C</sup> female mice with <italic>Trp53</italic><sup>Y217C/Y217C</sup> males, then administered supformin (LCC-12), a potent CD44 inhibitor known to attenuate inflammation in vivo, to pregnant mice by oral gavage. The administration of subformin led to a five-fold increase in the proportion of weaned <italic>Trp53</italic><sup>Y217C/Y217C</sup> females in the progeny, suggesting that reducing inflammation in utero rescued some of the <italic>Trp53</italic><sup>Y217C/Y217C</sup> female embryos. This new result is presented in Figure 5G and Supplementary Table S6, and mentioned in the abstract.</p><p>We believe that these new results, as well as the additional GSEA analyses revealing increased NFkB signaling in <italic>Trp53</italic><sup>Y217C/Y217C</sup> cells, further emphasize the importance of inflammation in the GOF of the p53<sup>Y217C</sup> mutant. Accordingly, we slightly modified the title of our article, to include the notion that <italic>Trp53</italic><sup>Y217C</sup> is an inflammation-prone mouse model. We also end the article by summarizing the effects of p53<sup>Y217C</sup> in vivo, in a new Supplementary Table S7 that compares the LOF effects of a p53 KO with the (LOF+GOF) effects of the p53<sup>Y217C</sup> mutant.</p><disp-quote content-type="editor-comment"><p>(3) Dominant negative effect - the authors' claim of lack of DN effect needs to be strengthened further, as most p53 hot-spot mutations do exhibit DN effect. At the minimum, the authors should perform additional treatment with nutlin and gamma irradiation (or cytotoxic/damaging agents) and examine a set of canonical p53 target genes by qRT-PCR to strengthen their claim.</p></disp-quote><p>Our previous data indicated identical tumor onset and survival in <italic>Trp53</italic><sup>+/Y217C</sup> and <italic>Trp53</italic><sup>+/-</sup> mice, leading us to conclude that, at least for spontaneous tumorigenesis, there was no evidence of a Dominant Negative Effect (DNE) in vivo. Here, we followed the referee’s suggestion and evaluated the possibility of a DNE in response to stress, by comparing WT, <italic>Trp53</italic><sup>+/Y217C</sup> and <italic>Trp53</italic><sup>+/-</sup> MEFs or thymocytes. We analyzed different types of stress (Nutlin, Doxorubicin, girradiation) and different types of cellular responses (transactivation of classical p53 target genes, cell cycle arrest, apoptosis), and the results lead us to conclude that there is little if any DNE also in response to various stresses. These new data are mentioned in a paragraph evaluating the possibility of DNE or GOF at the cellular level, and presented in a new Supplementary Figure S6.</p></body></sub-article></article>